Gastrointestinal stromal tumors (GIST) comprise less than 1% of all gastrointestinal (GI) tumors, but constitute the most common mesenchymal tumors and soft tissue sarcomas of the GI tract. They occur anywhere along the GI tract but are found most often in the stomach (60%) or small intestine (30%) and less frequently in the rectum, colon, or mesentery. In the United States, around 3300 to 6000 new cases of GIST are diagnosed each year. The vast majority of cases are sporadic, and older age is a recognized risk factor. Mutations in KIT and platelet-derived growth factor receptor-alpha (PDGFRA) are found in over 80% of all primary GISTs. Alterations in neurofibromatosis type 1 gene (NF1) and succinate dehydrogenase (SDH) complex (SDHC) genes as well as altered methylation of SDHC promoter have been described as oncogenic drivers in GIST without activating mutations in KIT or PDGFRA, and they have been linked to familial and heritable syndromes (NF1 and Carney-Stratakis syndrome).
Despite a wide variation in tumor size, location, and histologic subtypes (spindle cell, epithelioid cells, and mixed type), approximately 85% of all GISTs share oncogenic mutations in 1 of 2 receptor tyrosine kinases (TKs): KIT or PDGFRA. Constitutive activation of either of these TKs plays a central role in the oncogenic behavior of GIST. The early characterization of GIST mutational status is important in both the localized and metastatic settings to identify imatinib-resistant mutations (such as some primary KIT exon 17 mutations or PDGFRA D842V) or mutations that require a higher dose of imatinib. Patients with GIST lacking KIT or PDGFRA mutations usually do not benefit from imatinib, and standard treatment algorithms mostly do not apply. However, other mutations may be present in these patients, with the largest group represented by SDH-deficiency frequently associated with Carney or Carney-Stratakis-Syndrome. Other subtypes have mutations in NF1 (usually associated with neurofibromatosis type I) or in BRAF or KRAS. Very recently, casuistic cases of GIST-like tumors harboring NTRK translocations have further expanded the spectrum of molecular subtypes.
In the pre-tyrosine kinase inhibitor (TKI) era, GISTs (often categorized as gastric leiomyosarcomas or leiomyoblastomas) were treated within the subtype of agnostic sarcoma trials and lacked an effective systemic therapy. However, a deeper understanding of the molecular pathogenesis and driving role of the protooncogenes KIT and PDGFRA has transformed the treatment of both localized and metastatic diseases. Localized and resectable tumors are treated surgically which remains the mainstay of curative therapy for localized disease. Resected high-risk GIST is typically treated with adjuvant imatinib, whereas low-risk GIST is managed with surgery alone. Intermediate-risk GIST is managed on a per-case basis. In an advanced/metastatic setting, imatinib 400 mg daily is approved, with dose escalation to 800 mg at the time of progression, and has been shown to yield dramatic results in disease control. Imatinib-refractory patients are treated with sunitinib as a second-line therapy and regorafenib as third-line therapy on resistance or intolerance to sunitinib.
At diagnosis, a mutation in the KIT gene occurs in 80% of GISTs and is usually found in exon 11, and less commonly in exon 9. Both mechanisms cause ligand-independent receptor activation, which leads to uncontrolled cell growth and transformation. Primary mutations affect a loss-of-function mutation in the JM domain and lead to a shift in equilibrium toward a Type I active or on-state conformation of KIT and away from a Type II inactive or off-state conformation of KIT. Exon 11 primary mutations are the most commonly seen in GISTs (around 70% of cases), and derive significant benefit from treatment with imatinib in both the adjuvant and metastatic settings, achieving a 2-year relapse-free survival of ˜90% in the adjuvant setting, and a median event-free survival just under 2 years in the metastatic setting. Primary mutations (in treatment-naïve patients) in exon 9 affect the extracellular domain of KIT, mimicking conformational changes induced by ligand binding and triggering KIT receptor homodimerization. This dimerization leads to the activation of specific intracellular signaling pathways which can lead to cancer cell proliferation, survival, and resistance. Although less common than exon 11 mutations, exon 9 mutations (10%-15% of newly diagnosed cases) are most commonly seen in GISTs arising from the small intestine. Unlike exon 11 mutations, they benefit less from imatinib in both the adjuvant and metastatic settings.
Despite significant improvement in outcomes compared with those in the pre-mutation-driven/TKI therapy era, response to imatinib is not experienced by all patients, and most patients with GIST will ultimately develop resistance to imatinib, most commonly due to the development of secondary mutations in KIT. Secondary resistance mutations usually arise in the catalytic domain of the kinase: 1) at the switch pocket, which typically occur in KIT exons 13 and 14 or PDGFRA exons 14 and 15 and sterically disrupt drug binding or conformationally activate KIT, and 2) in the activation loop switch encoded by KIT exons 17 and 18 and PDGFRA 18. Activation loop mutations act by shifting the kinase into an activated Type I or on-state conformation that is less amenable to drug binding by any of the approved Type II TKIs. Although uncommon in primary GIST (1%-2% of newly diagnosed cases), mutations in exons 13, 14 and 17 are often responsible for acquired imatinib resistance, with exon 17 mutations alone accounting for as many as 50% of the acquired resistance cases to imatinib, and later to sunitinib. A need exists for a TKI that can broadly inhibit clinically relevant KIT and PDGFRA mutations.
Described herein are methods of treating a gastrointestinal stromal tumor in a patient in need thereof comprising administering to the patient a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
For example, in one embodiment described herein is a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient 100 mg to 300 mg, e.g., 150 mg, of ripretinib daily, wherein the patient's tumor has progressed from, or the patient was intolerant to, a previous first line administration of imatinib.
For example, in one embodiment described herein is a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient 100 mg to 250 mg, e.g., 150 mg, of ripretinib daily, wherein the patient's tumor has progressed from, or the patient was intolerant to, a previous first line administration of imatinib.
In another embodiment, described herein is a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient 100 mg to 600 mg, e.g., 100 mg to 250 mg, e.g., 150 mg, of ripretinib daily, wherein the patient's tumor has progressed from, or the patient was intolerant to, a previous first line administration of imatinib.
In another embodiment, described herein is a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient one or more tablets comprising ripretinib, e.g., tablets each comprising 50 mg to 100 mg of ripretinib, daily, wherein the patient's tumor has progressed from, or the patient was intolerant to, a previous first line administration of imatinib. In some examples, the tablets comprise 50 mg of ripretinib. In some embodiments, the tablets comprise 75 mg of ripretinib. In some embodiments, the tablets comprise 100 mg of ripretinib.
In another embodiment, described herein is a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient one or more tablets comprising ripretinib, e.g., tablets each comprising 50 mg to 100 mg of ripretinib, daily, wherein the patient's tumor has progressed from, or the patient was intolerant to, a previous first line administration of imatinib, a previous second line administration of sunitinib, and a previous third line administration of regorafenib or wherein the patient has a documented intolerance to one or more of imatinib, sunitinib and/or regorafenib. In some embodiments, the tablets comprise 50 mg of ripretinib. In some example, the tablets comprise 75 mg of ripretinib. In some example, the tablets comprise 100 mg of ripretinib. In another embodiment, described herein is a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient 100 mg to 250 mg of ripretinib daily, e.g., 150 mg, wherein the patient's tumor has progressed from, or the patient was intolerant to, a first line administration of imatinib, a second line administration of sunitinib, and a third line administration of regorafenib or wherein the patient has a documented intolerance to one or more of imatinib, sunitinib and/or regorafenib.
In another embodiment, described herein is a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient 100 mg to 600 mg of ripretinib daily, e.g., 100 mg to 250 mg, e.g., 100 mg to 500 mg, e.g., 100 mg to 250 mg, e.g., 150 mg, wherein the patient's tumor has progressed from, or the patient was intolerant to, a first line administration of imatinib, a second line administration of sunitinib, and a third line administration of regorafenib or wherein the patient has a documented intolerance to one or more of imatinib, sunitinib and/or regorafenib.
In another embodiment, described herein is a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient to the patient, on a daily basis, one or more tablets each comprising ripretinib, e.g., tablets each comprising 50 mg to 100 mg of ripretinib, wherein the patient's tumor has progressed from, or the patient was intolerant to, a first line administration of imatinib, a second line administration of sunitinib, and a third line administration of regorafenib or wherein the patient has a documented intolerance to one or more of imatinib, sunitinib and/or regorafenib. In some embodiment, the tablets comprise 50 mg of ripretinib. In some embodiment, the tablets comprise 75 mg of ripretinib. In some embodiment, the tablets comprise 100 mg of ripretinib.
In another embodiment, described herein is a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient 100 mg to 600 mg of ripretinib daily, e.g., 100 mg to 250 mg, e.g., 100 mg to 500 mg, e.g., 100 mg to 250 mg, e.g., 150 mg, e.g., 300 mg, wherein the patient was previously administered at least two tyrosine kinase inhibitors before administration of the ripretinib.
In another embodiment, described herein is a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient 150 mg of ripretinib once daily, wherein the patient was previously administered at least two tyrosine kinase inhibitors before administration of the ripretinib.
In another embodiment, described herein is a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient, on a daily basis, one or more tablets each comprising ripretinib, e.g., tablets each comprising 50 mg to 100 mg of ripretinib, wherein the patient was previously administered at least two tyrosine kinase inhibitors before administration of the ripretinib. In some embodiment, the tablets comprise 50 mg of ripretinib. In some embodiment, the tablets comprise 75 mg of ripretinib. In some embodiment, the tablets comprise 100 mg of ripretinib.
In another embodiment, described herein is a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient 150 mg of ripretinib once daily, wherein the patient was previously administered three or more kinase inhibitors before administration of the ripretinib. In some embodiments, after at least 4 weeks of the daily ripretinib administration, the patient has at least a 5-month progression-free survival as measured using mRECIST v1.1. In some embodiments, orally administering to the patient 150 mg of ripretinib once daily comprises administering to the patient three tablets each tablet comprising 50 mg of ripretinib. In some embodiments, one of the three or more kinase inhibitors is imatinib. In some embodiments, the patient was previously administered imatinib, sunitinib and regorafenib.
In another embodiment, described herein is a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient 150 mg daily ripretinib, wherein the patient's tumor has progressed from, or the patient was intolerant to, a first line administration of imatinib, a second line administration of sunitinib, and a third line administration of regorafenib.
In another embodiment, described herein is a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient 150 mg of ripretinib once or twice daily, wherein the patient's tumor has progressed from, or the patient was intolerant to, a previous first line administration of imatinib.
In another embodiment, described herein is a method for achieving at least 5 months of progression free survival as determined by mRECIST 1.1 in a patient having an advanced gastrointestinal stromal tumor, comprising orally administering to the patient 100, 150 200, or 300 mg of ripretinib daily or twice daily for at least 28 days.
In another embodiment, described herein is a method for achieving at least 5 months of progression free survival as determined by mRECIST 1.1 in a patient having an advanced gastrointestinal stromal tumor, comprising orally administering to the patient 100, 150, or 200 mg of ripretinib daily or twice daily for at least 28 days.
In another embodiment, descried herein is a method of treating a patient suffering from Grade 3 palmer-plantar erythrodysesthesia syndrome while being administered 150 mg ripretinib daily or twice daily, comprising withholding administration of ripretinib for at least 7 days or until the patient has less than or equal to Grade 1 palmer-plantar plantar erythrodysesthesia syndrome, then administering to the patient 100 mg daily (e.g., 100 mg once daily) ripretinib for at least 28 days.
In another embodiment, descried herein is a method of treating a patient suffering from Grade 2 palmer-plantar erythrodysesthesia syndrome upon administration of 150 mg ripretinib daily or twice daily, comprising a) withholding administration of ripretinib until the patient has less than or equal to Grade 1 palmer-plantar erythrodysesthesia syndrome or baseline; b) if the patient recovers from the palmer-plantar erythrodysesthesia syndrome within 7 days of withholding administration, then administering to the patient 150 mg daily ripretinib or c) if the patient has not recovered, then administering to the patient 100 mg daily ripretinib for at least 28 days.
In another embodiment, described herein is a method of treating a gastrointestinal stromal tumor in a patient in need thereof, wherein the patient is being treated concurrently with a CYP3A4 inhibitor, the method comprising: orally administering to the patient 100 mg or 150 mg of ripretinib, or a pharmaceutically acceptable salt thereof, once or twice daily, and wherein upon administration of the ripretinib and the CYP3A4 inhibitor, provides an increased ripretinib area under the plasma concentration curve (AUC0-inf) of 80% or more in the patient as compared to administration of ripretinib without concurrent treatment of the CYP3A4 inhibitor, and therefore the patient is at higher risk of an adverse event; and monitoring the patient more frequently, as compared to a patient not being treated with a CYP3A4 inhibitor, for the adverse event.
In another embodiment, described herein is a method of treating a gastrointestinal stromal tumor in a patient in need thereof, wherein the patient is being treated concurrently with a proton pump inhibitor, the method comprising: orally administering to the patient 100 mg or 150 mg of ripretinib, or a pharmaceutically acceptable salt thereof, once or twice daily, and wherein administration of the ripretinib and proton pump inhibitor to the patient provides no clinically significant difference in the plasma exposure of ripretinib in the patient as compared to administration of ripretinib without concurrent treatment of the proton pump inhibitor.
In another embodiment, described herein is a method of treating a gastrointestinal stromal tumor in a patient in need thereof, the method comprising orally administering to the patient 100 mg or 150 mg of ripretinib, or a pharmaceutically acceptable salt thereof, once or twice daily, wherein the ripretinib is administered to the patient with food or without food.
The features and other details of the disclosure will now be more particularly described. Certain terms employed in the specification, examples and appended claims are collected here. These definitions should be read in light of the remainder of the disclosure and as understood by a person of skill in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by a person of ordinary skill in the art.
As used herein, “ripretinib” is a compound represented by the following structure:
As used herein, “sunitinib” is a compound represented by the following structure:
As used herein, “imatinib” is a compound represented by the following structure:
As used herein, “regorafenib” is a compound represented by the following structure:
As used herein, “Compound A” is a compound represented by the following structure:
“Individual,” “patient,” or “subject” are used interchangeably herein and include any animal, including mammals, including mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and humans. The compounds described herein can be administered to a mammal, such as a human, but can also be administered to other mammals such as an animal in need of veterinary treatment, e.g., domestic animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like). The mammal treated in the methods described herein is desirably a mammal in which treatment of a disorder described herein is desired, such as a human.
The term “pharmaceutically acceptable salt(s)” as used herein refers to salts of acidic or basic groups that may be present in compounds used in the compositions. Compounds included in the present compositions that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including, but not limited to, malate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e., 1,1′-methylene-bis-(2-hydroxy-3-naphthoate)) salts.
As used herein, “treating” includes any effect, e.g., lessening, reducing, modulating, or eliminating, that results in the improvement of the condition, disease, disorder and the like.
Therapeutically effective amount” includes the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician. A compound described herein, e.g., ripretinib is administered in therapeutically effective amounts to treat a condition described herein, e.g., gastrointestinal stromal tumors. Alternatively, a therapeutically effective amount of a compound is the quantity required to achieve a desired therapeutic and/or prophylactic effect, such as an amount which results in the prevention of or a decrease in the symptoms associated with the condition.
As used herein, “AUC0-24 h” refers to the area under the plasma concentration-time curve from time zero to 24 hours for a compound described herein. As used herein, “AUC0-inf” refers to the area under the plasma concentration-time curve from time zero to infinite time for a compound described herein. As used herein, “Cmax” refers to the maximum plasma concentration of a compound described herein.
A compound described herein, e.g., ripretinib, can be formulated as a pharmaceutical composition using a pharmaceutically acceptable carrier and administered by a variety of routes. In some embodiments, such compositions are for oral administration. In some embodiments, compositions formulated for oral administration are provided as tablets. In some embodiments, such compositions are for parenteral (by injection) administration (e.g., a composition formulated for local injection at the site of a tumor, e.g., a diffuse-type giant cell tumor). In some embodiments, such compositions are for transdermal administration. In some embodiments, such compositions are for topical administration. In some embodiments, such compositions are for intravenous (IV) administration. In some embodiments, such compositions are for intramuscular (IM) administration. Such pharmaceutical compositions and processes for preparing them are well known in the art. See, e.g., REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY (A. Gennaro, et al., eds., 19th ed., Mack Publishing Co., 1995).
Methods of Treatment
Described herein are methods of treating gastrointestinal stromal tumors in a patient in need thereof. For example, the present disclosure relates to a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient 100 mg or more of ripretinib daily, e.g., 100 mg to 5000 mg, e.g., 100 mg to 500 mg, 100 mg to 250 mg, e.g., 150 mg, wherein the patient's tumor has progressed from, or the patient was intolerant to, a previous first line administration of imatinib. In some embodiments, the method comprises administering to the patient 110 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 120 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 130 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 140 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 150 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 200 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 250 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 300 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 350 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 400 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 450 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 500 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 550 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 600 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 650 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 700 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 750 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 800 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 850 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 900 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 950 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 1000 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 150 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 200 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 250 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 300 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 350 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 400 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 450 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 500 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 550 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 600 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 650 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 700 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 750 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 800 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 850 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 900 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 950 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 1000 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 150 mg of ripretinib twice daily. In some embodiments, the method comprises administering to the patient 200 mg of ripretinib twice daily. In some embodiments, the method comprises administering to the patient 250 mg of ripretinib twice daily. In some embodiments, the method comprises administering to the patient 300 mg of ripretinib twice daily. In some embodiments, the method comprises administering to the patient 350 mg of ripretinib twice daily. In some embodiments, the method comprises administering to the patient 400 mg of ripretinib twice daily. In some embodiments, the method comprises administering to the patient 450 mg of ripretinib twice daily. In some embodiments, the method comprises administering to the patient 500 mg of ripretinib twice daily.
In some embodiments, a patient was only previously treated with a first line administration of imatinib, e.g., only imatinib and no other therapeutic compounds had been administered to the patient before administration of ripretinib to the patient. For example, a patient was not previously administered with sunitinib and/or regorafenib, e.g., the patient was not previously given a second line administration of sunitinib therapy and/or a third-line administration of regorafenib therapy.
In some embodiments, the patient has a non-nodal tumor lesion of greater than or equal to 1.0 cm in the long axis or greater than or equal to double the slide thickness in the long axis, within 21 days prior to the first dose of ripretinib. Contemplated methods of treatment include administering ripretinib on a 42-day cycle, comprising daily administrations of ripretinib without administering sunitinib. After at least one 42-day cycle comprising daily administrations of ripretinib, the patient may have progression-free survival as measured using mRECIST v1.1. In some embodiments, the patient treated with daily administrations of ripretinib may have significant progression free survival (e.g., about 3 months progression free survival or more, e.g., about 6 months progression free survival, as compared to a second line daily administration of 50 mg sunitinib for four weeks followed by two weeks without daily administrations on a 42-day cycle, wherein the patient's tumor has progressed from, or the patient was intolerant to, the previous first line administration of imatinib.
Contemplated treatments with ripretinib may treat a broad spectrum of KIT and PDGFRA mutations. For example, a patient's tumor may have a KIT exon 9 mutation, a PDGFRA exon 18 mutation, a PDGFRA exon 12 mutation or a PDGFRA exon 18 activation loop mutation. For example, the patient's tumor mutation is a PDGFRA D842V mutation.
In some embodiments, a patient's tumor has an imatinib resistant mutation selected from the group consisting of a KIT exon 17 activation loop mutation, a KIT exon 18 activation loop mutation, a KIT exon 13 mutation, a KIT exon 14 mutation, a KIT exon 18 mutation, a PDGFRA exon 12 mutation, a PDGFRA exon 14 mutation, a PDGRFA exon 15 mutation, and a PDGFRA exon 18 activation loop mutation. For example, the imatinib resistant mutation is a PDGFRA D842V mutation.
In some embodiments, the patient's tumor has an imatinib resistant mutation selected from the group consisting of KIT exon 13 or 14 mutation, PDGFRA exon 14 or 15 mutation, a KIT 17 or 18 activation loop mutation, and a PDGFRA 18 activation loop mutation. For example, the patient's tumor has an imatinib resistant KIT exon 17 mutation.
Also described herein is a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient 100 mg or more, e.g., up to about 600 mg, e.g. up to about 250 mg, e.g., 100 mg or 150 mg, of ripretinib daily, wherein the patient's tumor has progressed from, or the patient was intolerant to, a first line administration of imatinib, a second line administration of sunitinib, and a third line administration of regorafenib or wherein the patient has a documented intolerance to one or more of imatinib, sunitinib and/or regorafenib. Contemplated methods of treatment include orally administering 100 mg, 150 mg or more of ripretinib daily without administering sunitinib on a 42-day cycle. In some embodiments, the method comprises administering to the patient 110 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 120 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 130 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 140 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 150 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 200 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 250 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 300 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 350 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 400 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 450 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 500 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 550 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 600 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 650 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 700 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 750 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 800 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 850 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 900 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 950 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 1000 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 150 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 200 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 250 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 300 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 350 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 400 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 450 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 500 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 550 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 600 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 650 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 700 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 750 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 800 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 850 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 900 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 950 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 1000 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 150 mg of ripretinib twice daily. In some embodiments, the method comprises administering to the patient 200 mg of ripretinib twice daily. In some embodiments, the method comprises administering to the patient 250 mg of ripretinib twice daily. In some embodiments, the method comprises administering to the patient 300 mg of ripretinib twice daily. In some embodiments, the method comprises administering to the patient 350 mg of ripretinib twice daily. In some embodiments, the method comprises administering to the patient 400 mg of ripretinib twice daily. In some embodiments, the method comprises administering to the patient 450 mg of ripretinib twice daily. In some embodiments, the method comprises administering to the patient 500 mg of ripretinib twice daily.
In some embodiments, a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient 100 mg or more of ripretinib daily, e.g., up to about 600 mg, e.g., 100 mg to 250 mg, e.g., 100 mg to 500 mg, e.g., 100 mg to 250 mg, e.g., 150 mg, wherein the patient was previously administered at least two tyrosine kinase inhibitors, is contemplated. Contemplated methods of treatment include orally administering 100 mg, 150 mg or more of ripretinib daily without administering sunitinib on a 42-day cycle. In some embodiments, the method comprises administering to the patient 110 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 120 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 130 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 140 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 150 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 200 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 250 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 300 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 350 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 400 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 450 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 500 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 550 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 600 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 650 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 700 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 750 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 800 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 850 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 900 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 950 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 1000 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 100 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 150 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 200 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 250 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 300 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 350 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 400 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 450 mg of ripretinib daily. In some embodiments, the method comprises administering to the patient 500 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 550 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 600 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 650 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 700 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 750 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 800 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 850 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 900 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 950 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 1000 mg of ripretinib once daily. In some embodiments, the method comprises administering to the patient 150 mg of ripretinib twice daily. In some embodiments, the method comprises administering to the patient 200 mg of ripretinib twice daily. In some embodiments, the method comprises administering to the patient 250 mg of ripretinib twice daily. In some embodiments, the method comprises administering to the patient 300 mg of ripretinib twice daily. In some embodiments, the method comprises administering to the patient 350 mg of ripretinib twice daily. In some embodiments, the method comprises administering to the patient 400 mg of ripretinib twice daily. In some embodiments, the method comprises administering to the patient 450 mg of ripretinib twice daily. In some embodiments, the method comprises administering to the patient 500 mg of ripretinib twice daily. In some embodiments, the patient has previously been administered two separate tyrosine kinase inhibitors, each selected from the group consisting of imatinib, sunitinib, regorafenib, lapatinib, gefitinib, erlotinib, vatalanib, crenolanib, and pharmaceutically acceptable salts thereof. In some embodiments, each of the tyrosine kinase inhibitors is independently selected from the group consisting of imatinib, sunitinib, and regorafenib. In some embodiments, each of the tyrosine kinase inhibitors is independently selected from the group consisting of imatinib mesylate, sunitinib malate, and regorafenib.
In some embodiments of the methods described herein, the patient is orally administered one or more tablets comprising ripretinib. For example, the disclosed methods include a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient one or more tablets comprising ripretinib, e.g., tablets each comprising 50 mg to 100 mg of ripretinib, daily, wherein the patient's tumor has progressed from, or the patient was intolerant to, a previous first line administration of imatinib. In some embodiments, the patient is administered one tablet comprising ripretinib. In some embodiments, the patient is administered one tablet comprising 50 mg of ripretinib. In some embodiments, the patient is administered one tablet comprising 50 mg of ripretinib once daily. In some embodiments, the patient is administered two tablets each comprising 50 mg of ripretinib. In some embodiments, the patient is administered two tablets each comprising 50 mg of ripretinib once daily. In some embodiments, the patient is administered three tablets each comprising 50 mg of ripretinib. In some embodiments, the patient is administered three tablets each comprising 50 mg of ripretinib once daily. In some embodiments, the patient is administered four tablets each comprising 50 mg of ripretinib. In some embodiments, the patient is administered four tablets each comprising 50 mg of ripretinib once daily. In some embodiments, the patient is administered five tablets each comprising 50 mg of ripretinib. In some embodiments, the patient is administered five tablets each comprising 50 mg of ripretinib once daily. In some embodiments, the patient is administered six tablets each comprising 50 mg of ripretinib. In some embodiments, the patient is administered six tablets each comprising 50 mg of ripretinib once daily.
Additionally, the disclosed methods include a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient, on a daily basis, one or more tablets each comprising ripretinib, e.g., tablets each comprising 50 mg to 100 mg of ripretinib, wherein the patient's tumor has progressed from, or the patient was intolerant to, a first line administration of imatinib, a second line administration of sunitinib, and a third line administration of regorafenib or wherein the patient has a documented intolerance to one or more of imatinib, sunitinib and/or regorafenib. In some embodiments, the patient is administered one tablet comprising ripretinib. In some embodiments, the patient is administered one tablet comprising 50 mg of ripretinib. In some embodiments, the patient is administered one tablet comprising 50 mg of ripretinib once daily. In some embodiments, the patient is administered two tablets each comprising 50 mg of ripretinib. In some embodiments, the patient is administered, once daily, two tablets each comprising 50 mg of ripretinib. In some embodiments, the patient is administered three tablets each comprising 50 mg of ripretinib. In some embodiments, the patient is administered, once daily, three tablets each comprising 50 mg of ripretinib once daily.
In some embodiments, provided is a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient, on a daily basis, one or more tablets each comprising ripretinib, e.g., tablets each comprising 50 mg to 100 mg of ripretinib, wherein the patient was previously administered at least two tyrosine kinase inhibitors before administration of the ripretinib. In some embodiments, the patient is administered one tablet comprising ripretinib. In some embodiments, the patient is administered one tablet comprising 50 mg of ripretinib. In some embodiments, the patient is administered one tablet comprising 50 mg of ripretinib once daily. In some embodiments, the patient is administered two tablets each comprising 50 mg of ripretinib. In some embodiments, the patient is administered, once daily, two tablets each comprising 50 mg of ripretinib. In some embodiments, the patient is administered three tablets each comprising 50 mg of ripretinib. In some embodiments, the patient is administered, once daily, three tablets each comprising 50 mg of ripretinib. In some embodiments, the patient has previously been administered two separate tyrosine kinase inhibitors, each selected from the group consisting of imatinib, sunitinib, regorafenib, lapatinib, gefitinib, erlotinib, vatalanib, crenolanib, and pharmaceutically acceptable salts thereof. In some embodiments, each of the tyrosine kinase inhibitors is independently selected from the group consisting of imatinib, sunitinib, and regorafenib. In some embodiments, each of the tyrosine kinase inhibitors is independently selected from the group consisting of imatinib mesylate, sunitinib malate, and regorafenib.
In another embodiment, described herein is a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient 150 mg of ripretinib once daily, wherein the patient was previously administered three or more kinase inhibitors before administration of the ripretinib. In some embodiments, after at least 4 weeks of the daily ripretinib administration, the patient has at least a 5-month progression-free survival as measured using mRECIST v1.1. In some embodiments, orally administering to the patient 150 mg of ripretinib once daily comprises administering to the patient three tablets each tablet comprising 50 mg of ripretinib. In some embodiments, one of the three or more kinase inhibitors is imatinib. In some embodiments, the patient was previously administered imatinib, sunitinib and regorafenib.
In some embodiments, if the patient suffers from a Grade 3 palmer-plantar erythrodysesthesia syndrome upon administration of the ripretinib, the method further comprises a) withholding administration of ripretinib for at least 7 days or until the patient has less than or equal to Grade 1 palmer-plantar erythrodysesthesia syndrome, then administering to the patient 100 mg daily (e.g., 100 mg once daily) ripretinib for at least 28 days.
In some embodiments, if the patient suffers from a Grade 2 palmer-plantar erythrodysesthesia syndrome upon administration of the ripretinib, the method further comprises: a) withholding administration of ripretinib until the patient has less than or equal to Grade 1 palmer-plantar erythrodysesthesia syndrome or baseline; b) if the patient recovers from the palmer-plantar erythrodysesthesia syndrome within 7 days of withholding administration, then administering to the patient 150 mg daily ripretinib or c) if the patient has not recovered, then administering to the patient 100 mg daily ripretinib for at least 28 days.
In another embodiment, described herein is a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient 150 mg daily ripretinib, wherein the patient's tumor has progressed from, or the patient was intolerant to, a first line administration of imatinib, a second line administration of sunitinib, and a third line administration of regorafenib.
In some embodiments, if the patient suffers from a Grade 3 palmer-plantar erythrodysesthesia syndrome upon administration of the ripretinib, the method further comprises a) withholding administration of ripretinib for at least 7 days or until the patient has less than or equal to Grade 1 palmer-plantar erythrodysesthesia syndrome, then administering to the patient 100 mg daily (e.g., 100 mg once daily) ripretinib for at least 28 days.
In some embodiments, if the patient suffers from a Grade 2 palmer-plantar erythrodysesthesia syndrome upon administration of the ripretinib, the method further comprises: a) withholding administration of ripretinib until the patient has less than or equal to Grade 1 palmer-plantar erythrodysesthesia syndrome or baseline; b) if the patient recovers from the palmer-plantar erythrodysesthesia syndrome within 7 days of withholding administration, then administering to the patient 150 mg daily ripretinib or c) if the patient has not recovered, then administering to the patient 100 mg daily ripretinib for at least 28 days.
In another embodiment, described herein is a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient 150 mg of ripretinib once or twice daily, wherein the patient's tumor has progressed from, or the patient was intolerant to, a previous first line administration of imatinib. In some embodiments, if the patient suffers from Grade 3 palmer-plantar erythrodysesthesia syndrome upon administration of the ripretinib, the method further comprises a) withholding administration of ripretinib for at least 7 days or until the patient has less than or equal to Grade 1 palmer-plantar erythrodysesthesia syndrome, then administering to the patient 100 mg daily (e.g., 100 mg once daily) ripretinib for at least 28 days. In some embodiments, if the patient suffers from Grade 3 palmer-plantar erythrodysesthesia syndrome upon administration of the ripretinib, the method further comprises a) withholding administration of ripretinib for at least 7 days or until the patient has less than or equal to Grade 1 palmer-plantar erythrodysesthesia syndrome, then administering to the patient 100 mg daily (e.g., 100 mg once daily) ripretinib for at least 28 days. In some embodiments, if the patient suffers from Grade 2 palmer-plantar erythrodysesthesia syndrome upon administration of the ripretinib, the method further comprises: a) withholding administration of ripretinib until the patient has less than or equal to Grade 1 palmer-plantar erythrodysesthesia syndrome or baseline; b) if the patient recovers from the palmer-plantar erythrodysesthesia syndrome within 7 days of withholding administration, then administering to the patient 150 mg daily ripretinib or c) if the patient has not recovered, then administering to the patient 100 mg daily ripretinib for at least 28 days. In some embodiments, if the patient suffers from a Grade 3 adverse disorder selected from arthralgia or myalgia upon administration of the ripretinib, the method further comprises: a) withholding administration of ripretinib until the patient has less than or equal to Grade 1 adverse disorder, then administering to the patient 100 mg daily (e.g., 100 mg once daily) ripretinib for at least 28 days. In some embodiments, if the patient suffers from Grade 3 hypertension upon administration of the ripretinib, the method further comprises withholding administration of ripretinib until the patient's blood pressure is controlled, and if the patient has less than or equal to Grade 1 blood pressure is, administering to the patient 150 mg daily ripretinib, or if the patient has more than Grade 1 blood pressure, administering 100 mg daily (e.g., 100 mg once daily) ripretinib.
In another embodiment, described herein is a method for achieving at least 5 months of progression free survival as determined by mRECIST 1.1 in a patient having an advanced gastrointestinal stromal tumor, comprising orally administering to the patient 100, 150 200, or 300 mg of ripretinib daily or twice daily for at least 28 days. In some embodiments, the patient has been administered at least one previous kinase inhibitor. In some embodiments, the patient has been administered at least three previous kinase inhibitors. In some embodiments, the at least one previous kinase inhibitor is imatinib. In some embodiments, comprising orally administering to the patient 100, 150 or 200 mg of ripretinib daily or twice daily for at least 4 months.
In another embodiment, described herein is a method for achieving at least 5 months of progression free survival as determined by mRECIST 1.1 in a patient having an advanced gastrointestinal stromal tumor, comprising orally administering to the patient 100, 150, or 200 mg of ripretinib daily or twice daily for at least 28 days. In some embodiments, the patient has been administered at least one previous kinase inhibitor. In some embodiments, the patient has been administered at least three previous kinase inhibitors. In some embodiments, the at least one previous kinase inhibitor is imatinib. In some embodiments, comprising orally administering to the patient 100, 150, or 200 mg of ripretinib daily or twice daily for at least 4 months.
In another embodiment, descried herein is a method of treating a patient suffering from Grade 3 palmer-plantar erythrodysesthesia syndrome while being administered 150 mg ripretinib daily or twice daily, comprising withholding administration of ripretinib for at least 7 days or until the patient has less than or equal to Grade 1 palmer-plantar erythrodysesthesia syndrome, then administering to the patient 100 mg daily (e.g., 100 mg once daily) ripretinib for at least 28 days.
In another embodiment, descried herein is a method of treating a patient suffering from Grade 2 palmer-plantar erythrodysesthesia syndrome upon administration of 150 mg ripretinib daily or twice daily, comprising a) withholding administration of ripretinib until the patient has less than or equal to Grade 1 palmer-plantar erythrodysesthesia syndrome or baseline; b) if the patient recovers from the palmer-plantar erythrodysesthesia syndrome within 7 days of withholding administration, then administering to the patient 150 mg daily ripretinib or c) if the patient has not recovered, then administering to the patient 100 mg daily ripretinib for at least 28 days.
In another embodiment, described herein is a method of treating a gastrointestinal stromal tumor in a patient in need thereof, wherein the patient is being treated concurrently with a CYP3A4 inhibitor, the method comprising: orally administering to the patient 100 mg or 150 mg of ripretinib, or a pharmaceutically acceptable salt thereof, once or twice daily, and wherein upon administration of the ripretinib and the CYP3A4 inhibitor, provides an increased ripretinib area under the plasma concentration curve (AUC0-inf) of 80% or more in the patient as compared to administration of ripretinib without concurrent treatment of the CYP3A4 inhibitor, and therefore the patient is at higher risk of an adverse event; and monitoring the patient more frequently, as compared to a patient not being treated with a CYP3A4 inhibitor, for the adverse event. In some embodiments, if the patient suffers from a Grade 3 palmer-plantar erythrodysesthesia syndrome adverse event, the method further comprises a) withholding administration of ripretinib for at least 7 days or until the patient has less than or equal to Grade 1 palmer-plantar erythrodysesthesia syndrome, then administering to the patient 100 mg daily ripretinib for at least 28 days. In some embodiments, if the patient suffers from Grade 2 palmer-plantar erythrodysesthesia syndrome upon administration of the ripretinib, the method further comprises: a) withholding administration of ripretinib until the patient has less than or equal to Grade 1 palmer-plantar erythrodysesthesia syndrome or baseline; b) if the patient recovers from the palmer-plantar erythrodysesthesia syndrome within 7 days of withholding administration, then administering to the patient 150 mg daily ripretinib or c) if the patient has not recovered, then administering to the patient 100 mg daily ripretinib for at least 28 days. In some embodiments, the CYP3A4 inhibitor is selected from the group consisting of itraconazole, ketoconazole, clarithromycin, and indinavir. In some embodiments, the CYP3A4 inhibitor is itraconazole. In some embodiments, the patient has previously been administered one or more tyrosine kinase inhibitors, each selected from the group consisting of imatinib, sunitinib, regorafenib, lapatinib, gefitinib, erlotinib, vatalanib, crenolanib, and pharmaceutically acceptable salts thereof.
In another embodiment, described herein is a method of treating a gastrointestinal stromal tumor in a patient in need thereof, wherein the patient is being treated concurrently with a proton pump inhibitor, the method comprising: orally administering to the patient 100 mg or 150 mg of ripretinib, or a pharmaceutically acceptable salt thereof, once or twice daily, and wherein administration of the ripretinib and proton pump inhibitor to the patient provides no clinically significant difference in the plasma exposure of ripretinib in the patient as compared to administration of ripretinib without concurrent treatment of the proton pump inhibitor. In some embodiments, the proton pump inhibitor is selected from the group consisting of pantoprazole, omeprazole, lansoprazole, rabeprazole, esomeprazole, and dexlansoprazole. In some embodiments, the proton pump inhibitor is pantoprazole. In some embodiments, the patient is being treated concurrently with 40 mg of the proton pump inhibitor once daily.
In another embodiment, described herein is a method of treating a gastrointestinal stromal tumor in a patient in need thereof, the method comprising orally administering to the patient 100 mg or 150 mg of ripretinib, or a pharmaceutically acceptable salt thereof, once or twice daily, wherein the ripretinib is administered to the patient with food or without food. In some embodiments, the food comprises a high-fat meal (e.g., a high-fat meal described herein).
In some embodiments, the therapeutic efficacy of ripretinib is determined by the progression-free survival of the patient after independent radiologic review using Response Evaluation Criteria in Solid Tumors (RECIST). In some embodiments, the therapeutic efficacy of ripretinib is determined by the progression-free survival of the patient after independent radiologic review using modified Response Evaluation Criteria in Solid Tumors (mRECIST). In some embodiments, the therapeutic efficacy of ripretinib is determined by the Objective Response Rate (ORR), Time to Tumor Progression (TTP) or Overall Survival (OS) of the patient after independent radiologic review using mRECIST. In some embodiments, the therapeutic efficacy of ripretinib is determined by the progression-free survival of the patient based on investigator assessment. In some embodiments, the therapeutic efficacy of ripretinib is determined by the quality of life of the patient in accordance with European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer 30-item (EORTC-QLQ-C30) and the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaires. In some embodiments, the therapeutic efficacy of ripretinib is determined by the disease control rate of the patient. In some embodiments, the therapeutic efficacy of ripretinib is determined by the duration of response of the patient.
After at least one month, two months, e.g., 42 days or more of treatment with ripretinib, the patient may have a progression-free survival as measured using mRECIST v1.1. As another example, the patient may have a least a 5 or 6 month progression-free survival as compared to placebo after at least 4 weeks of daily administration of ripretinib, and/or for example, after 4 weeks of daily administration of ripretinib, significantly reduced the risk of disease progression or death by 85%.
In some embodiments, the patient has at least one measurable tumor lesion according to modified RECIST Version 1.1 within 21 days prior to the first dose of ripretinib. In some embodiments, the patient has a non-nodal tumor lesion of greater than or equal to 1.0 cm in the long axis or greater than or equal to double the slide thickness in the long axis, within 21 days prior to the first dose of ripretinib.
In some embodiments, the patient's tumor has a KIT exon 9 mutation, a PDGFRA exon 18 mutation, a PDGFRA exon 12 mutation or a PDGFRA exon 18 activation loop mutation. For example, the patient's tumor mutation is a PDGFRA D842V mutation.
In some embodiments, the patient's tumor has an imatinib resistant, sunitinib resistant, and/or regorafenib resistant mutation selected from the group consisting of a KIT exon 17 activation loop mutation, a KIT exon 18 activation loop mutation, a KIT exon 13 mutation, a KIT exon 14 mutation, a KIT exon 18 mutation, a PDGFRA exon 12 mutation, a PDGFRA exon 14 mutation, a PDGRFA exon 15 mutation, and a PDGFRA exon 18 activation loop mutation. For example, the resistant mutation is a PDGFRA D842V mutation.
In some embodiments, the patient's tumor has a drug resistant mutation selected from the group consisting of KIT exon 13 or 14 mutation, PDGFRA exon 14 or 15 mutation, a KIT 17 or 18 activation loop mutation, and a PDGFRA 18 activation loop mutation. For example, the tumor has a drug resistant KIT exon 17 mutation.
Dose Modifications
Dose modifications may be made in the methods of administering ripretinib described herein as a result of adverse events experienced by the patient. In some embodiments, the dose modification is a dose interruption. In some embodiments, the dose modification is a permanent discontinuation in dosing. In some embodiments, the dose modification is a dose reduction. In some embodiments, the dose of ripretinib administered to the patient is reduced from 150 mg once daily, e.g., three tablets each comprising 50 mg of ripretinib, to 100 mg once daily, e.g., two tablets each comprising 50 mg of ripretinib. In some embodiments, the dose of ripretinib administered to the patient is reduced from 150 mg once daily, e.g., three tablets each comprising 50 mg of ripretinib, to 50 mg once daily, e.g., one tablet comprising 50 mg of ripretinib. In some embodiments, the adverse reaction is selected from the group consisting of a hand-foot skin reaction (e.g., palmar-plantar erythrodysesthesia syndrome), hypertension, arthralgia, and myalgia.
In some embodiments, the adverse event is graded in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03 (e.g., baseline, Grade 1, Grade 2, Grade 3, or Grade 4). In some embodiments, the dose modification is a dose interruption (e.g., a dose interruption of at least 7 days) as a result of a Grade 2 adverse event. In some embodiments, dosing resumes at the same dose level before the dose interruption if the adverse event is lowered to Grade 1 or baseline within a first time period (e.g., within 7 days). In some embodiments, dosing resumes at a reduced dose level before the dose interruption if the adverse event is lowered to Grade 1 or baseline after a first time period (e.g., after 7 days). In some embodiments, the reduced dose level is re-escalated to the dose level prior to the dose interruption if the adverse event is lowered to Grade 1 or baseline after a first time period but is maintained as a Grade 1 or baseline adverse event after a second time period (e.g., after 28 days). In some embodiments, the dose modification is a dose interruption (e.g., a dose interruption of at least 7 days up to a maximum of 28 days) as a result of a Grade 3 adverse event. In some embodiments, dosing is continued at a reduced level after the dose interruption. In some embodiments, the dose modification is a permanent discontinuation in dosing as a result of a Grade 4 adverse event (e.g., Grade 4 hypertension).
A patient can be administered an additional treatment in response to an adverse event or to prevent an adverse event from occurring. In some embodiments, a patient suffering from an adverse dermatologic reaction, e.g., a hand-foot skin reaction, e.g., palmar-plantar erythrodysesthesia syndrome, is administered a topical composition (e.g., an emollient) to treat the adverse dermatologic reaction. In some embodiments, the patient is administered the topical composition (e.g., an emollient) based on the severity of the adverse dermatologic reaction, e.g., a Grade 2, Grade 3 adverse dermatologic reaction, e.g., a Grade 1, Grade 2, or Grade 3 hand-foot skin reaction, e.g., a Grade 1, Grade 2 or Grade 3 palmar-plantar erythrodysesthesia syndrome. In some embodiments, the topical composition (e.g., an emollient) is administered to the patient during a dose interruption of ripretinib. In some embodiments, the topical composition (e.g., an emollient) is administered to the patient contemporaneously with a dose of ripretinib, e.g., a reduced dose of ripretinib.
A patient can also be administered an additional treatment prior to, or during administration of ripretinib in accordance with the methods described herein to prevent or ameliorate an adverse event. In some embodiments, the patient is administered a topical composition (e.g., an emollient) before and/or during ripretinib administration to prevent or ameliorate the onset of an adverse dermatologic reaction, e.g., a hand-foot skin reaction, e.g., palmar-plantar erythrodysesthesia syndrome.
Study Design. Approximately 358 eligible patients will be randomized into two cohorts in a 1:1 ratio in which one cohort undergoes continuous 42-day cycles of receiving ripretinib dosed at 150 mg daily (179 patients) and the other cohort receives sunitinib dosed at 50 mg daily for 4 weeks and then 2 weeks off on 42-day cycles (179 patients).
Given the mutation-driven natural history of GIST and the well-described relationship between secondary mutations and emergence of resistance to first- and second-line TKIs, the results of this study will evaluate ripretinib compared with sunitinib as second-line therapy in patients with GIST following imatinib therapy.
The primary end point of the study is to assess the progression-free survival (PFS) of ripretinib by blinded independent central review (BICR) using modified Response Evaluation Criteria in Solid Tumors version 1.1 (mRECIST v1.1). The key secondary efficacy end points include the assessment of ORR by BICR using mRECIST v1.1 and OS.
Statistical Analysis. PFS is defined as the time from randomization to the date of the first documented progression of disease or death due to any cause and is based on BICR assessment of the primary end point. OS is defined as the time from randomization to the date of death due to any cause. OS and PFS with 95% CI will be summarized using Kaplan-Meier methodology; point estimates of hazard ratios will be obtained from a Cox regression model. Objective response is defined as a CR or PR by BICR assessment using mRECIST v1.1.
This study was a randomized (2:1), double-blind, placebo-controlled, international, multicenter study to evaluate the safety, tolerability, and efficacy of ripretinib compared to placebo in 129 patients with advanced GIST whose previous therapies have included at least imatinib, sunitinib, and regorafenib. Patients were randomized 2:1 to either 150 mg of ripretinib or placebo once daily. The primary efficacy endpoint is progression-free survival (PFS) as determined by independent radiologic review using modified Response Evaluation Criteria in Solid Tumors (RECIST). Secondary endpoints as determined by independent radiologic review using modified RECIST include Objective Response Rate (ORR), Time to Tumor Progression (TTP) and Overall Survival (OS).
Results. This study achieved its primary endpoint of improved PFS as determined by blinded independent central radiologic review using modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Ripretinib demonstrated a median PFS of 6.3 months (27.6 weeks) compared to 1.0 month (4.1 weeks) in the placebo arm and significantly reduced the risk of disease progression or death by 85% (HR of 0.15, p<0.0001) compared to placebo. PFS rates at 6 months were 51% (95% CI: 39.4, 61.4) for ripretinib and 3.2% (95% CI: 0.2, 13.8) for placebo. Plots of survival probability with respect to PFS for patients on ripretinib and patients on placebo are shown in
For the key secondary endpoint of objective response rate (ORR), as determined by blinded independent central radiologic review using modified RECIST version 1.1, ripretinib demonstrated an ORR of 9.4% compared with 0% for placebo (p-value=0.0504), which was not statistically significant. Ripretinib in this study also showed a clinically meaningful improvement over placebo in terms of the secondary endpoint overall survival (OS) (median OS 15.1 months vs. 6.6 months, HR=0.36, nominal p-value=0.0004; OS rates at 12 months were 65.4% (95% CI: 51.6, 76.1) for ripretinib and 25.9% (95% CI: 7.2, 49.9) for placebo); however, because statistical significance was not achieved for ORR, the hypothesis testing of OS was not formally performed. Plots of survival probability with respect to OS of patients on ripretinib and patients on placebo are shown in
Patients that successfully crossed over from placebo had smaller tumors vs those that did not crossover (median sum of longest diameter of target lesions 119.4 mm vs 183.3 mm). In addition, the median age of those who crossed over was higher than those who did not cross over (68.0 vs 58.0 years) and none had a baseline Eastern Cooperative Oncology Group (ECOG) score of 2, while 3 patients in the group that did not cross over had an ECOG score of 2. Patients that crossed over had a median PFS of 20.0 weeks [95% CI, 8.0−NE] vs 27.6 weeks seen in the initial ripretinib arm and 4.1 weeks seen in the initial placebo arm, respectively. Median OS in patients who crossed over was 11.6 months, vs. 15.1 months in patients initially randomized to ripretinib and 1.8 months in patients on placebo who did not crossover. TEAEs during the crossover period suggest no safety concerns when compared to the safety profile of patients initially assigned to ripretinib.
Ripretinib was generally well tolerated and the adverse event results were consistent with data from previously presented Phase 1 study results. Grade 3 or 4 treatment-emergent adverse events (TEAEs) occurred in 42 (49%) patients on the ripretinib arm compared to 19 (44%) on the placebo arm. Grade 3 or 4 TEAEs>5% of patients in the ripretinib arm were anemia (9%; n=8), abdominal pain (7%; n=6) and hypertension (7%; n=6). Grade 3 or 4 TEAEs>5% of patients in the placebo arm were anemia (14%; n=6). Table 1 lists TEAEs>15% in the ripretinib arm compared to placebo.
In table 1, (1) indicates that the safety population includes 128 patients. One patient was randomized to placebo but did not receive study drug.
Patient Reported Outcomes
Patient reported outcomes were assessed by EQ-5D-5L, which provides a visual analogue scale (VAS), and EORTC QLQ-C30, which provides physical function and role function scales. The EQ-5D-5L VAS (or EQ-VAS) records the respondent's overall current health on a vertical visual analogue scale and provides a quantitative measure of the patient's perception of overall health. These patient outcomes were reported across 28-day cycles of receiving 150 mg QD ripretinib or placebo.
The EORTC QLQ-C30 is an assessment of function and symptoms of therapy by cancer patient, and is not specific to any cancer. The EORTC QLQ-C30 is a 30-question plus one global health status, including 5 functional scales, 3 symptom scales and a global health status.
Open-Label Phase and Dose Escalation
Patients whose disease progressed during the double blind phase of the study were escalated to 150 mg BID ripretinib, continued at the 150 mg QD dose, or discontinued in an open label-phase of the study. Table 8 shows a comparison of patients that received 150 mg QD ripretinib at the data cutoff time point of the double blind phase and the data cutoff time point of the open-label phase. The data in Table 8 suggest that data cut 9 months after the primary double-blind analysis has shown improvement in mOS and a similar mPFS in the ripretinib arm.
In the study, at least 31 patients dose escalated to 150 mg BID ripretinib in an open-label phase upon disease progression. PFS studies in the double-blind and open-label periods for these patients are depicted in
Wild Type (KIT and PDGFRA) Mutations
PFS data among patients with wild-type KIT or PDGFRA mutations were further evaluated at 150 mg ripretinib QD. PFS data of patients with these wild-type KIT and PDGFRA mutations are shown in
Additional Mutational Analyses
Progression free survival PFS and overall survival (OS) data based on patients with a primary Exon 11 mutation or patients with a non-Exon 11 mutation are shown in
Progression free survival PFS and overall survival (OS) data based on patients with a primary Exon 11 mutation or those with a primary Exon 9 mutation are shown in
Furthermore, progression free survival PFS and overall survival (OS) data based on patients with a primary Exon 11 mutation, or a primary Exon 9 mutation, or other mutations, and wild type (KIT and PDGFRA) are shown in
PFS studies for patients with certain primary mutations (Exon 9 or Exon 11) who dose escalated to 150 mg BID ripretinib are shown in
Additionally,
Results. Data from 178 GIST patients receiving ripretinib at doses of ≥100 mg daily are noted in Table 2. The table includes investigator-assessed objective response rate (ORR) by best response, disease control rate (DCR) and median progression free survival (mPFS), all of which were determined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
In Table 2, (1) indicates overall number of patients (n=178) remains the same as prior data presented at ESMO 2018; based on additional data cleaning, one patient from each of 2nd line and 4th/≥4th line were reclassified as 3rd line patients; (2) refers to median treatment durations were: 2nd line=44 weeks, 3rd line=48 weeks, 4th line=46 weeks and ≥4th line=29 weeks; (3) refers to including 60 patients who elected for intra-patient dose escalation from 150 mg QD to 150 mg BID; and (4) refers to the number of patients including 60 patients from 4th line.
Ripretinib was generally well tolerated and the updated adverse events were consistent with previously presented Phase 1 data in patients with GIST. Grade 3 or 4 treatment-emergent adverse events (TEAEs) in >5% of patients were lipase increased (18%; n=33), anemia (11%; n=20), hypertension (7%; n=13) and abdominal pain (6%; n=11). 13% of patients (n=24) experienced TEAEs leading to study treatment discontinuation, 17% of patients (n=31) experienced TEAEs leading to dose reduction and 49% of patients (n=88) had TEAEs leading to study drug interruption. Table 3 lists TEAEs>10% for GIST patients treated with ≥100 mg of ripretinib daily.
In table 3, (1) refers to including one patient that only participated in the food effect portion of the Phase 1 study; and (2) indicates that dermatology skin exams were implemented to better evaluate skin lesions.
Efficacy and safety results from the escalation and expansion phases of a phase 1 study for patients with GIST treated at ripretinib 150 mg QD as the starting dose in 28-day cycles are presented. Local, investigator-assessed Response Evaluation Criteria in Solid Tumors (RECIST 1.1) response assessments were performed every 2 cycles, and patients in the expansion cohorts who progressed per RECIST 1.1 were allowed to dose escalate to 150 mg BID.
142 patients with GIST in the escalation and expansion phases were treated at 150 mg QD dose. Number of patients by line of therapy were as follows: 31 2nd line, 28 3rd line, and 83≥4th line patients. 135 patients (95.1%) had KIT-mutant GIST, and 7 patients (4.9%) had PDGFRA-mutant GIST.
Results on the efficacy by line of therapy in patients with GIST receiving ripretinib 150 mg QD are presented in Table 4. For example, the confirmed-only complete response (CR), partial response (PR), stable disease, and progressive disease are presented in Table 4. The objective response rate data in Table 4 relates to the proportion of patients with CR+PR. The median PFS data in Table 4 refers to progression-free survival per investigator assessment, by line of therapy. PFS plots by line of therapy are also shown in
In Table 4: a64 subjects escalated to 150 mg BID among patients with GIST in the 150 mg QD dose group. CI, confidence interval; CR, complete response; NE, not estimable; ORR, objective response rate; PFS, progression-free survival; PR, partial response; SD, standard deviation. Local (investigator) response assessment.
In subjects dose escalated to 150 mg BID, PFS before (PFS1) and after (PFS2) dose escalation was evaluated and is shown in
Mutational Analysis
If dose modifications of ripretinib are required due to adverse reactions, the following protocol will be applied: reduce the dose in 50 mg (one tablet) increments; the lowest recommended dose of ripretinib is 50 mg once daily. Ripretinib dosage reductions for adverse reactions are summarized in Table 5.
Dosing will be reduced, interrupted, or discontinued for certain toxicities. See Table 6 for dose modification guidelines.
aGraded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03
The safety of ripretinib and the impact of alopecia and palmar-plantar erythrodysesthesia (PPES) on patient-reported outcomes (PROs) of patients treated in the study described in Example 2 herein are described. Ripretinib had a favorable overall safety and tolerability profile in the trial of Example 2. When stratified by alopecia and PPES, patient reported assessments of function, overall health, and overall quality of life were maintained over time. For both alopecia and PPES, onset and maximum severity occurred almost simultaneously, indicating that these events generally did not progressively worsen. Overall, these results suggest that alopecia and PPES are manageable and that ripretinib treatment offsets any negative impact associated with these AEs.
Patient reported outcomes (PROs) were assessed with questions from the EuroQol 5D (EQ 5D 5L) and the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30).
Generalized estimating equation (GEE) models were used in statistical analyses in which: Repeated measures models across visits where the outcome was 1 of the 5 PROs; models were built only for ripretinib patients; for alopecia patients, cycles 1 and 2 were excluded to account for median time of alopecia onset; covariates were sex, alopecia/PPES (yes/no), and Eastern Cooperative Oncology Group (ECOG) score at baseline; and when there was no end date for the AE, it was coded conservatively as having extended to the last visit of the double blind period.
In the ripretinib arm, the most common treatment-emergent adverse event (TEAE) was alopecia (51.8%) and the most common grade ¾ TEAE was anemia (9.4%). The highest severity classification for alopecia is grade 2; therefore, no patients in either arm had grade ¾ alopecia. Alopecia was slightly more common in femalesys males in the ripretinib arm (56.8% vs 43.2%). In the ripretinib arm, 21.2% of patients reported PPES; no patients had grade 3 PPES (grade 3 is the highest severity classification for PPES). There were no serious adverse events of alopecia or PPES reported. Within the ripretinib arm, 7.1%, 23.5%, and 5.9% of patients experienced a TEAE leading to dose reduction, dose interruption, or death, respectively, compared with 2.3%, 20.9%, and 23.3% in the placebo arm. In patients receiving ripretinib, the median worst grade of alopecia occurred very shortly after the median first appearance (
Table 7 shows a GEE analysis summary of the association between alopecia and PPES with the 5 PRO measures in patients taking ripretinib. In a repeated measures analysis, there was a trend toward an improvement of the 5 PROs among patients with alopecia (Table 7). The presence of alopecia was associated with better self-reported overall quality of life (Table 7). This was statistically significant at P<0.01, but did not exceed the threshold for meaningful change. There was no association between PPES and the 5 PRO measures (Table 7).
Longitudinal graphs out to Cycle 10, Day 1 demonstrate similar trends in mean change from baseline for the 5 PROs for patients receiving ripretinib that developed alopecia or PPES and those that did not (
Coadministration of 150 mg QD ripretinib with a strong CYP3A inhibitor increased the exposure of ripretinib and its active metabolite (Compound A), which may increase the risk of adverse reactions. Coadministration of ripretinib with itraconazole (a strong CYP3A inhibitor and also a P-gp inhibitor) increased ripretinib Cmax by 36% and AUC0-inf by 99% and also increased Compound A AUC0-inf by 99% with no change in its Cmax.
The effect of a proton-pump inhibitor on the exposure of ripretinib was evaluated. No clinically significant differences in the plasma exposure to ripretinib and Compound A were observed when ripretinib was coadministered with pantoprazole, a proton-pump inhibitor. Although ripretinib has pH-dependent solubility, concomitant administration of 40 mg QD pantoprazole with 150 mg QD ripretinib did not affect ripretinib exposure.
The effect of a high-fat breakfast on ripretinib and Compound A exposure was evaluated. A high fat meal consisted of approximately 150, 250, and 500-600 calories from protein, carbohydrate, and fat, respectively. Following administration of ripretinib with a high-fat meal at a 150 mg dose, ripretinib AUC0-24 h and Cmax were higher by 30% and 22%, respectively. For the metabolite Compound A, AUC0-24 h and Cmax were higher by 47% and 66%, respectively. The food effect is not considered to be clinically significant based on exposure-response analysis. Therefore, ripretinib may be taken with or without food at approximately same time each day.
Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific embodiments described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.
This application is a continuation of U.S. Ser. No. 17/727,307 filed Apr. 22, 2022, which is a continuation of U.S. Ser. No. 17/583,985 filed Jan. 25, 2022 which is a continuation of U.S. Ser. No. 17/180,218 filed Feb. 19, 2021, which is a divisional application of U.S. Ser. No. 17/028,640 filed Sep. 22, 2020, which is a continuation of International Application Number PCT/US2020/045876 filed Aug. 12, 2020, which claims priority to U.S. Ser. No. 62/885,797 filed Aug. 12, 2019, U.S. Ser. No. 62/904,198 filed Sep. 23, 2019, U.S. Ser. No. 62/926,281 filed Oct. 25, 2019, U.S. Ser. No. 62/936,018 filed Nov. 15, 2019, U.S. Ser. No. 62/968,927 Jan. 31, 2020, U.S. Ser. No. 62/968,945 filed Jan. 31, 2020, U.S. Ser. No. 63/023,921 filed May 13, 2020, and U.S. Ser. No. 63/023,936 filed May 13, 2020, the contents of each of which are incorporated herein by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
3528980 | Islip | Sep 1970 | A |
3818024 | Krenzer | Jun 1974 | A |
3939122 | Merten et al. | Feb 1976 | A |
3949002 | Feasey et al. | Apr 1976 | A |
4093624 | Revankar et al. | Jun 1978 | A |
4296237 | Cragoe, Jr. et al. | Oct 1981 | A |
4366189 | Burdeska et al. | Dec 1982 | A |
4432992 | Cragoe, Jr. et al. | Feb 1984 | A |
4525450 | Itoh et al. | Jun 1985 | A |
4816454 | Zoller et al. | Mar 1989 | A |
5103014 | Musser et al. | Apr 1992 | A |
5162360 | Creswell et al. | Nov 1992 | A |
5189045 | Peglion et al. | Feb 1993 | A |
5319099 | Kamata et al. | Jun 1994 | A |
5494925 | Court et al. | Feb 1996 | A |
5514691 | Chan et al. | May 1996 | A |
5614532 | Carling et al. | Mar 1997 | A |
5621010 | Sueda et al. | Apr 1997 | A |
5658924 | Matsuura et al. | Aug 1997 | A |
5721231 | Moriwaki et al. | Feb 1998 | A |
5811456 | Seman et al. | Sep 1998 | A |
6020357 | Pinto et al. | Feb 2000 | A |
6028085 | Bromidge | Feb 2000 | A |
6080763 | Regan et al. | Jun 2000 | A |
6123964 | Asgharnejad et al. | Sep 2000 | A |
6147088 | Goulet et al. | Nov 2000 | A |
6197599 | Chin et al. | Mar 2001 | B1 |
6235786 | Dai et al. | May 2001 | B1 |
6294573 | Curtin et al. | Sep 2001 | B1 |
6319921 | Cirillo et al. | Nov 2001 | B1 |
6410254 | Finer et al. | Jun 2002 | B1 |
6500628 | Robison | Dec 2002 | B1 |
6525046 | Cirillo et al. | Feb 2003 | B1 |
6645990 | Askew et al. | Nov 2003 | B2 |
6763607 | Beyerinck et al. | Jul 2004 | B2 |
6916924 | Tan et al. | Jul 2005 | B2 |
6973741 | Beyerinck et al. | Dec 2005 | B2 |
7071199 | Hirst et al. | Jul 2006 | B1 |
7135550 | Come et al. | Nov 2006 | B2 |
7144911 | Flynn et al. | Dec 2006 | B2 |
7202257 | Flynn et al. | Apr 2007 | B2 |
7211575 | Moss et al. | May 2007 | B2 |
7279576 | Flynn et al. | Oct 2007 | B2 |
7342037 | Flynn et al. | Mar 2008 | B2 |
7531566 | Flynn et al. | May 2009 | B2 |
7666895 | Flynn et al. | Feb 2010 | B2 |
7737283 | Flynn et al. | Jun 2010 | B2 |
7790756 | Flynn et al. | Sep 2010 | B2 |
7897762 | Flynn et al. | Mar 2011 | B2 |
8143293 | Flynn et al. | Mar 2012 | B2 |
8163756 | Flynn et al. | Apr 2012 | B2 |
8188113 | Flynn et al. | May 2012 | B2 |
8278331 | Flynn et al. | Oct 2012 | B2 |
8343550 | Beyerinck et al. | Jan 2013 | B2 |
8461179 | Flynn et al. | Jun 2013 | B1 |
8486951 | Flynn et al. | Jul 2013 | B2 |
8569319 | Flynn et al. | Oct 2013 | B2 |
8586565 | Flynn et al. | Nov 2013 | B2 |
8637672 | Flynn et al. | Jan 2014 | B2 |
8669289 | Li | Mar 2014 | B2 |
8741911 | Allgeier et al. | Jun 2014 | B2 |
8828443 | Beyerinck et al. | Sep 2014 | B2 |
8921565 | Flynn et al. | Dec 2014 | B2 |
8940756 | Flynn et al. | Jan 2015 | B2 |
9012635 | Flynn et al. | Apr 2015 | B2 |
9133183 | Flynn et al. | Sep 2015 | B2 |
9181223 | Kaufman et al. | Nov 2015 | B2 |
9187474 | Flynn et al. | Nov 2015 | B2 |
9193719 | Flynn et al. | Nov 2015 | B2 |
9248584 | Friesen et al. | Feb 2016 | B2 |
9265731 | Ray et al. | Feb 2016 | B2 |
9309224 | Flynn et al. | Apr 2016 | B2 |
9334267 | Flynn et al. | May 2016 | B2 |
9339467 | Beyerinck et al. | May 2016 | B2 |
9382228 | Flynn et al. | Jul 2016 | B2 |
9387202 | Flynn et al. | Jul 2016 | B2 |
9457019 | Flynn et al. | Oct 2016 | B2 |
9724664 | Friesen et al. | Aug 2017 | B2 |
10300443 | Friesen et al. | May 2019 | B2 |
10383941 | Beyerinck et al. | Aug 2019 | B2 |
10675602 | Friesen et al. | Jun 2020 | B2 |
10966966 | Soto et al. | Apr 2021 | B2 |
20020058678 | Cirillo et al. | May 2002 | A1 |
20020077486 | Scarborough et al. | Jun 2002 | A1 |
20020165394 | Dumas et al. | Nov 2002 | A1 |
20020193405 | Askew et al. | Dec 2002 | A1 |
20030060455 | Moss et al. | Mar 2003 | A1 |
20030105139 | Gaster et al. | Jun 2003 | A1 |
20030144278 | Riedl et al. | Jul 2003 | A1 |
20030181442 | Riedl et al. | Sep 2003 | A1 |
20030207870 | Dumas et al. | Nov 2003 | A1 |
20030216396 | Dumas et al. | Nov 2003 | A1 |
20030232865 | Cirillo et al. | Dec 2003 | A1 |
20040043388 | Come et al. | Mar 2004 | A1 |
20040067938 | Zhang et al. | Apr 2004 | A1 |
20040102636 | Miller et al. | May 2004 | A1 |
20040157827 | Pevarello et al. | Aug 2004 | A1 |
20040167224 | Ozaki et al. | Aug 2004 | A1 |
20040171075 | Flynn et al. | Sep 2004 | A1 |
20040180906 | Flynn et al. | Sep 2004 | A1 |
20040229937 | Dumas et al. | Nov 2004 | A1 |
20050014753 | Ding et al. | Jan 2005 | A1 |
20050148605 | Grotzfeld et al. | Jul 2005 | A1 |
20050165024 | Milanov et al. | Jul 2005 | A1 |
20050165031 | Grotzfeld et al. | Jul 2005 | A1 |
20050165074 | Grotzfeld et al. | Jul 2005 | A1 |
20050171171 | Mehta et al. | Aug 2005 | A1 |
20050171172 | Lai et al. | Aug 2005 | A1 |
20050192314 | Mehta et al. | Sep 2005 | A1 |
20050197371 | Milanov et al. | Sep 2005 | A1 |
20050256174 | Wood et al. | Nov 2005 | A1 |
20050261315 | Mehta et al. | Nov 2005 | A1 |
20050267182 | Milanov et al. | Dec 2005 | A1 |
20050288286 | Flynn et al. | Dec 2005 | A1 |
20060229337 | Brittelli et al. | Oct 2006 | A1 |
20060247186 | Carter et al. | Nov 2006 | A1 |
20070037794 | Ungashe et al. | Feb 2007 | A1 |
20070078121 | Flynn et al. | Apr 2007 | A1 |
20070155764 | Lang et al. | Jul 2007 | A1 |
20070179130 | Bannen | Aug 2007 | A1 |
20070191336 | Flynn et al. | Aug 2007 | A1 |
20070244120 | Dumas et al. | Oct 2007 | A1 |
20070293685 | Fritch et al. | Dec 2007 | A1 |
20080009527 | Dumas et al. | Jan 2008 | A1 |
20080045531 | Flynn et al. | Feb 2008 | A1 |
20080045706 | Flynn et al. | Feb 2008 | A1 |
20080064717 | Iyengar et al. | Mar 2008 | A1 |
20080090856 | Flynn et al. | Apr 2008 | A1 |
20080113967 | Flynn et al. | May 2008 | A1 |
20080114006 | Flynn et al. | May 2008 | A1 |
20080132506 | Flynn et al. | Jun 2008 | A1 |
20080176846 | Chianelli et al. | Jul 2008 | A1 |
20080187978 | Flynn et al. | Aug 2008 | A1 |
20080194836 | Gharbaoui et al. | Aug 2008 | A1 |
20080200530 | Unett et al. | Aug 2008 | A1 |
20080207699 | Hoelzemann et al. | Aug 2008 | A1 |
20080214545 | Lee et al. | Sep 2008 | A1 |
20080220497 | Flynn et al. | Sep 2008 | A1 |
20080221192 | Wan et al. | Sep 2008 | A1 |
20080248487 | Flynn et al. | Oct 2008 | A1 |
20080248548 | Flynn et al. | Oct 2008 | A1 |
20080300281 | Dumas et al. | Dec 2008 | A1 |
20090069310 | Flynn et al. | Mar 2009 | A1 |
20090075986 | Flynn et al. | Mar 2009 | A1 |
20090093526 | Miller et al. | Apr 2009 | A1 |
20090099190 | Flynn et al. | Apr 2009 | A1 |
20090105230 | Flynn et al. | Apr 2009 | A1 |
20090124633 | Jonczyk et al. | May 2009 | A1 |
20090137021 | Flynn et al. | May 2009 | A1 |
20090192307 | Michelotti et al. | Jul 2009 | A1 |
20090215799 | Stieber et al. | Aug 2009 | A1 |
20090281089 | Gunzner et al. | Nov 2009 | A1 |
20090312349 | Flynn et al. | Dec 2009 | A1 |
20090325945 | Niculescu-Duvaz et al. | Dec 2009 | A1 |
20100075971 | Dumas et al. | Mar 2010 | A1 |
20100160292 | Whitney et al. | Jun 2010 | A1 |
20100209420 | Lamb et al. | Aug 2010 | A1 |
20100286215 | Pelcman et al. | Nov 2010 | A1 |
20100298290 | Anand et al. | Nov 2010 | A1 |
20110077240 | Mannion et al. | Mar 2011 | A1 |
20110092461 | Gunzner et al. | Apr 2011 | A1 |
20110098293 | Mannion et al. | Apr 2011 | A1 |
20110112193 | Nilsson et al. | May 2011 | A1 |
20110124640 | Liu et al. | May 2011 | A1 |
20110136760 | Flynn et al. | Jun 2011 | A1 |
20110136809 | Lee et al. | Jun 2011 | A1 |
20110183997 | Chianelli et al. | Jul 2011 | A1 |
20110195110 | Smith et al. | Aug 2011 | A1 |
20120094980 | Gunzner et al. | Apr 2012 | A1 |
20120114605 | Li | May 2012 | A1 |
20120214808 | Bloxham et al. | Aug 2012 | A1 |
20120225057 | Flynn et al. | Sep 2012 | A1 |
20120270878 | Miller et al. | Oct 2012 | A1 |
20120289540 | Flynn et al. | Nov 2012 | A1 |
20130071403 | Rolland et al. | Mar 2013 | A1 |
20130225581 | Furuta et al. | Aug 2013 | A1 |
20130296326 | Pollock | Nov 2013 | A1 |
20140088075 | Flynn et al. | Mar 2014 | A1 |
20140107100 | Rice et al. | Apr 2014 | A1 |
20140147415 | Moussy et al. | May 2014 | A1 |
20140179632 | Mannion et al. | Jun 2014 | A1 |
20140296248 | Bernards et al. | Oct 2014 | A1 |
20140296267 | Fry et al. | Oct 2014 | A1 |
20140336210 | Christopher et al. | Nov 2014 | A1 |
20150031648 | Le Tiran et al. | Jan 2015 | A1 |
20150073141 | Teegarden et al. | Mar 2015 | A1 |
20150105550 | Gunzner et al. | Apr 2015 | A1 |
20150111879 | Gunzner et al. | Apr 2015 | A1 |
20150133462 | Singh et al. | May 2015 | A1 |
20150218652 | Doebele et al. | Aug 2015 | A1 |
20150225369 | Wuchere-Plietker et al. | Aug 2015 | A1 |
20150246033 | Flynn et al. | Sep 2015 | A1 |
20150275306 | Bernards et al. | Oct 2015 | A1 |
20150320759 | Flynn et al. | Nov 2015 | A1 |
20160009709 | Cheve et al. | Jan 2016 | A1 |
20160045532 | Roberts et al. | Feb 2016 | A1 |
20160152569 | Gunzner-Toste et al. | Jun 2016 | A1 |
20160166679 | Low et al. | Jun 2016 | A1 |
20160222012 | Ruan | Aug 2016 | A1 |
20160289663 | Kiyokawa et al. | Oct 2016 | A1 |
20160374990 | Teegarden et al. | Dec 2016 | A1 |
20170015627 | Gunzner-Toste et al. | Jan 2017 | A1 |
20170121321 | Crews et al. | May 2017 | A1 |
20170174750 | Lim et al. | Jun 2017 | A1 |
20170349880 | Doucey et al. | Dec 2017 | A1 |
20170360791 | Joshi-Hangal et al. | Dec 2017 | A1 |
20180000771 | Inoue et al. | Jan 2018 | A1 |
20180071302 | Abella et al. | Mar 2018 | A1 |
20180071303 | Abella et al. | Mar 2018 | A1 |
20190091217 | Flynn et al. | Mar 2019 | A1 |
20200129489 | Flynn et al. | Apr 2020 | A1 |
20200253973 | Flynn et al. | Aug 2020 | A1 |
20200352920 | Flynn et al. | Nov 2020 | A1 |
20200354346 | Flynn et al. | Nov 2020 | A1 |
20200354352 | Flynn et al. | Nov 2020 | A1 |
20210015801 | Flynn et al. | Jan 2021 | A1 |
Number | Date | Country |
---|---|---|
101528744 | Sep 2009 | CN |
101553232 | Oct 2009 | CN |
102731385 | Oct 2012 | CN |
105461699 | Apr 2016 | CN |
106822128 | Jun 2017 | CN |
108379591 | Aug 2018 | CN |
1115350 | Oct 1961 | DE |
4343831 | Jun 1995 | DE |
0021228 | Jan 1981 | EP |
0025232 | Mar 1981 | EP |
0154190 | Sep 1985 | EP |
0661276 | Jul 1995 | EP |
0692483 | Nov 1995 | EP |
0739884 | Oct 1996 | EP |
0867435 | Sep 1998 | EP |
0927555 | Jul 1999 | EP |
928790 | Jul 1999 | EP |
0956855 | Nov 1999 | EP |
1281399 | Feb 2003 | EP |
2858646 | Apr 2015 | EP |
2337554 | Aug 1977 | FR |
2396549 | Feb 1979 | FR |
971307 | Sep 1964 | GB |
1410279 | Oct 1975 | GB |
2220206 | Jan 1990 | GB |
59-177557 | Aug 1984 | JP |
9-221476 | Aug 1997 | JP |
2000275886 | Oct 2000 | JP |
2001-2687 | Jan 2001 | JP |
59-15247 | May 2016 | JP |
20130065368 | Jun 2013 | KR |
WO-199119708 | Dec 1991 | WO |
WO-199208693 | May 1992 | WO |
WO-199418176 | Aug 1994 | WO |
WO-199421617 | Sep 1994 | WO |
WO-199424095 | Oct 1994 | WO |
WO-1995006044 | Mar 1995 | WO |
WO-199515954 | Jun 1995 | WO |
WO-199529902 | Nov 1995 | WO |
WO-199534540 | Dec 1995 | WO |
WO-199616046 | May 1996 | WO |
WO-199619477 | Jun 1996 | WO |
WO-1996023783 | Aug 1996 | WO |
WO-199734900 | Sep 1997 | WO |
WO-1997037989 | Oct 1997 | WO |
WO-199740028 | Oct 1997 | WO |
WO-1997045400 | Dec 1997 | WO |
WO-199822103 | May 1998 | WO |
WO-199852558 | Nov 1998 | WO |
WO-199915164 | Apr 1999 | WO |
WO-199923091 | May 1999 | WO |
WO-199923093 | May 1999 | WO |
WO-19993 7622 | Jul 1999 | WO |
WO-199932106 | Jul 1999 | WO |
WO-199932110 | Jul 1999 | WO |
WO-199932111 | Jul 1999 | WO |
WO-199932455 | Jul 1999 | WO |
WO-199959959 | Nov 1999 | WO |
WO-200006550 | Feb 2000 | WO |
WO-200007980 | Feb 2000 | WO |
WO-200018738 | Apr 2000 | WO |
WO-200021927 | Apr 2000 | WO |
WO-200041698 | Jul 2000 | WO |
WO-2000042012 | Jul 2000 | WO |
WO-200043384 | Jul 2000 | WO |
WO-200055139 | Sep 2000 | WO |
WO-200059506 | Oct 2000 | WO |
WO-2000071515 | Nov 2000 | WO |
WO-200112621 | Feb 2001 | WO |
WO-200114372 | Mar 2001 | WO |
WO-200174771 | Oct 2001 | WO |
WO-200196298 | Dec 2001 | WO |
WO-200200647 | Jan 2002 | WO |
WO-200214291 | Feb 2002 | WO |
WO-200214311 | Feb 2002 | WO |
WO-2002026712 | Apr 2002 | WO |
WO-200228835 | Apr 2002 | WO |
WO-200234 727 | May 2002 | WO |
WO-2002060869 | Aug 2002 | WO |
WO-2002060876 | Aug 2002 | WO |
WO-2002062763 | Aug 2002 | WO |
WO-2002070662 | Sep 2002 | WO |
WO-2003005999 | Jan 2003 | WO |
WO-2003047579 | Jun 2003 | WO |
WO-2003053368 | Jul 2003 | WO |
WO-2003059373 | Jul 2003 | WO |
WO-2003068223 | Aug 2003 | WO |
WO-2003068229 | Aug 2003 | WO |
WO-2003072577 | Sep 2003 | WO |
WO-2003084539 | Oct 2003 | WO |
WO-2004004720 | Jan 2004 | WO |
WO-2004056783 | Jul 2004 | WO |
WO-2004060305 | Jul 2004 | WO |
WO-2004060306 | Jul 2004 | WO |
WO-2004061084 | Jul 2004 | WO |
WO-2004078128 | Sep 2004 | WO |
WO-2004078746 | Sep 2004 | WO |
WO-2004113352 | Dec 2004 | WO |
WO-2005002673 | Jan 2005 | WO |
WO-2005012254 | Feb 2005 | WO |
WO-2005024755 | Mar 2005 | WO |
WO-2005034869 | Apr 2005 | WO |
WO-2005048948 | Jun 2005 | WO |
WO-2005103011 | Nov 2005 | WO |
WO-2005110994 | Nov 2005 | WO |
WO-2006014290 | Feb 2006 | WO |
WO-2006014325 | Feb 2006 | WO |
WO-2006018662 | Feb 2006 | WO |
WO-2006028958 | Mar 2006 | WO |
WO-2006039718 | Apr 2006 | WO |
WO-2006040056 | Apr 2006 | WO |
WO-2006046552 | May 2006 | WO |
WO-2006052936 | May 2006 | WO |
WO-2006062984 | Jun 2006 | WO |
WO-2006071940 | Jul 2006 | WO |
WO-2006072589 | Jul 2006 | WO |
WO-2006078610 | Jul 2006 | WO |
WO-2006081034 | Aug 2006 | WO |
WO-2006081335 | Aug 2006 | WO |
WO-2006099075 | Sep 2006 | WO |
WO-2006105844 | Oct 2006 | WO |
WO-2007008917 | Jan 2007 | WO |
WO-2007042321 | Apr 2007 | WO |
WO-2007064872 | Jun 2007 | WO |
WO-2007076473 | Jul 2007 | WO |
WO-2007081690 | Jul 2007 | WO |
WO-2007115670 | Oct 2007 | WO |
WO-2007125330 | Nov 2007 | WO |
WO-2007136465 | Nov 2007 | WO |
WO-2007137107 | Nov 2007 | WO |
WO-2008033858 | Mar 2008 | WO |
WO-2008033999 | Mar 2008 | WO |
WO-2008034008 | Mar 2008 | WO |
WO-2008046003 | Apr 2008 | WO |
WO-2008051757 | May 2008 | WO |
WO-2008131227 | Oct 2008 | WO |
WO-2008131253 | Oct 2008 | WO |
WO-2008140895 | Nov 2008 | WO |
WO-2009030887 | Mar 2009 | WO |
WO-2009076454 | Jun 2009 | WO |
WO-2009109035 | Sep 2009 | WO |
WO-2009126863 | Oct 2009 | WO |
WO-2009127822 | Oct 2009 | WO |
WO-2009138758 | Nov 2009 | WO |
WO-2010011837 | Jan 2010 | WO |
WO-2010051373 | May 2010 | WO |
WO-2010124283 | Oct 2010 | WO |
WO-2010135524 | Nov 2010 | WO |
WO-2011067306 | Jun 2011 | WO |
WO-2011123788 | Oct 2011 | WO |
WO-2011137342 | Nov 2011 | WO |
WO-2011139891 | Nov 2011 | WO |
WO-2011150198 | Dec 2011 | WO |
WO-2012008563 | Jan 2012 | WO |
WO-2012019015 | Feb 2012 | WO |
WO-2012035131 | Mar 2012 | WO |
WO-2012071519 | May 2012 | WO |
WO-2012097021 | Jul 2012 | WO |
WO-2012138783 | Oct 2012 | WO |
WO-2013036232 | Mar 2013 | WO |
WO-2013043569 | Mar 2013 | WO |
WO-2013066440 | May 2013 | WO |
WO-2013078295 | May 2013 | WO |
WO-2013134243 | Sep 2013 | WO |
WO-2013134252 | Sep 2013 | WO |
WO-2013134298 | Sep 2013 | WO |
WO-2013177420 | Nov 2013 | WO |
WO-2013184119 | Dec 2013 | WO |
WO-2014015056 | Jan 2014 | WO |
WO-2014032755 | Mar 2014 | WO |
WO-2014036387 | Mar 2014 | WO |
WO-2014037480 | Mar 2014 | WO |
WO-2014040242 | Mar 2014 | WO |
WO-2014040549 | Mar 2014 | WO |
WO-2014058317 | Apr 2014 | WO |
WO-2014102376 | Jul 2014 | WO |
WO-2014102377 | Jul 2014 | WO |
WO-2014139458 | Sep 2014 | WO |
WO-2014145004 | Sep 2014 | WO |
WO-2014145015 | Sep 2014 | WO |
WO-2014145023 | Sep 2014 | WO |
WO-2014145025 | Sep 2014 | WO |
WO-2014145028 | Sep 2014 | WO |
WO-2014145029 | Sep 2014 | WO |
WO-2014160183 | Oct 2014 | WO |
WO-2014182643 | Nov 2014 | WO |
WO-2015011399 | Jan 2015 | WO |
WO-2015069217 | May 2015 | WO |
WO-2015069266 | May 2015 | WO |
WO-2015076213 | May 2015 | WO |
WO-2015092423 | Jun 2015 | WO |
WO-2015106292 | Jul 2015 | WO |
WO-2015106294 | Jul 2015 | WO |
WO-2015148620 | Oct 2015 | WO |
WO-2015184443 | Dec 2015 | WO |
WO-2016061228 | Apr 2016 | WO |
WO-2016061231 | Apr 2016 | WO |
WO-2016096903 | Jun 2016 | WO |
WO-2016103223 | Jun 2016 | WO |
WO-2016114322 | Jul 2016 | WO |
WO-2016135046 | Sep 2016 | WO |
WO-2016154524 | Sep 2016 | WO |
WO-2016196141 | Dec 2016 | WO |
WO-2017013160 | Jan 2017 | WO |
WO-2017042944 | Mar 2017 | WO |
WO-2017079267 | May 2017 | WO |
WO-2017117182 | Jul 2017 | WO |
WO-2017146794 | Aug 2017 | WO |
WO-2017146795 | Aug 2017 | WO |
WO-2017214514 | Dec 2017 | WO |
WO-2018005737 | Jan 2018 | WO |
WO-2018052053 | Mar 2018 | WO |
WO-2018053189 | Mar 2018 | WO |
WO-2018106595 | Jun 2018 | WO |
WO-2018195450 | Oct 2018 | WO |
WO-2018222173 | Dec 2018 | WO |
WO-2018222644 | Dec 2018 | WO |
WO-2020185812 | Sep 2020 | WO |
Entry |
---|
Jean-Yves Blay, et al., Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial, The Lancet Oncology, vol. 21, Issue 7, pp. 923-934 (2020). (Year: 2020). |
U.S. Appl. No. 11/963,740, filed Dec. 21, 2007, Patented, U.S. Pat. No. 8,163,756. |
U.S. Appl. No. 11/870,388, filed Oct. 10, 2007, Patented, U.S. Pat. No. 7,790,756. |
U.S. Appl. No. 12/829,561, filed Jul. 2, 2010, Patented, U.S. Pat. No. 8,586,565. |
U.S. Appl. No. 11/854,354, filed Sep. 12, 2007, Patented, U.S. Pat. No. 8,188,113. |
U.S. Appl. No. 10/746,460, filed Dec. 24, 2003, Patented, U.S. Pat. No. 7,144,911. |
U.S. Appl. No. 10/886,329, filed Jul. 6, 2004, Patented, U.S. Pat. No. 7,202,257. |
U.S. Appl. No. 11/450,840, filed Jun. 9, 2006, Patented, U.S. Pat. No. 7,342,037. |
U.S. Appl. No. 11/336,708, filed Jan. 20, 2006, Patented, U.S. Pat. No. 7,531,566. |
U.S. Appl. No. 11/450,850, filed Jun. 9, 2006, Patented, U.S. Pat. No. 7,666,895. |
U.S. Appl. No. 10/746,607, filed Dec. 24, 2003, Patented, U.S. Pat. No. 7,279,576. |
U.S. Appl. No. 11/854,293, filed Sep. 12, 2007, Patented, U.S. Pat. No. 7,897,762. |
U.S. Appl. No. 12/105,408, filed Apr. 18, 2008, Patented, U.S. Pat. No. 8,143,293. |
U.S. Appl. No. 13/590,955, filed Aug. 21, 2012, Patented, U.S. Pat. No. 8,486,951. |
U.S. Appl. No. 11/450,849, filed Jun. 9, 2006, Patented, U.S. Pat. No. 7,737,283. |
U.S. Appl. No. 13/785,575, filed Mar. 5, 2013, Patented, U.S. Pat. No. 8,741,911. |
U.S. Appl. No. 12/608,578, filed Oct. 29, 2009, Patented, U.S. Pat. No. 8,278,331. |
U.S. Appl. No. 13/098,247, filed Apr. 29, 2011, Patented, U.S. Pat. No. 8,569,319. |
U.S. Appl. No. 13/559,170, filed Jul. 26, 2012, Patented, U.S. Pat. No. 8,637,672. |
U.S. Appl. No. 14/214,134, filed Mar. 14, 2014, Patented, U.S. Pat. No. 9,133,183. |
U.S. Appl. No. 14/383,803, filed Mar. 5, 2013, Patented, U.S. Pat. No. 9,187,474. |
U.S. Appl. No. 13/491,394, filed Jun. 7, 2012, Patented, U.S. Pat. No. 8,461,179. |
U.S. Appl. No. 13/801,753, filed Mar. 13, 2013, Patented, U.S. Pat. No. 8,940,756. |
U.S. Appl. No. 16/387,315, filed Apr. 17, 2019, Pending. |
U.S. Appl. No. 14/214,127, filed Mar. 14, 2014, Patented, U.S. Pat. No. 9,012,635. |
U.S. Appl. No. 13/683,277, filed Nov. 21, 2012, Patented, U.S. Pat. No. 8,921,565. |
U.S. Appl. No. 14/549,125, filed Nov. 20, 2014, Patented, U.S. Pat. No. 9,387,202. |
U.S. Appl. No. 14/214,160, filed Mar. 14, 2014, Patented, U.S. Pat. No. 9,193,719. |
U.S. Appl. No. 14/214,171, filed Mar. 14, 2014, Patented, U.S. Pat. No. 9,181,223. |
U.S. Appl. No. 14/214,185, filed Mar. 14, 2014, Patented, U.S. Pat. No. 9,382,228. |
U.S. Appl. No. 14/214,179, filed Mar. 14, 2014, Patented, U.S. Pat. No. 9,309,224. |
U.S. Appl. No. 14/383,799, filed Mar. 5, 2013, Patented, U.S. Pat. No. 9,334,267. |
U.S. Appl. No. 14/535,900, filed Nov. 7, 2014, Patented, U.S. Pat. No. 9,457,019. |
U.S. Appl. No. 15/957,888, filed Apr. 19, 2018, Pending, US 2019-0091217 A1. |
U.S. Appl. No. 16/617,721, filed Nov. 27, 2019, Pending, US 2020-0129489 A1. |
U.S. Appl. No. 17/028,591, filed Sep. 22, 2020, Pending, US 2021-0015801 A1. |
U.S. Appl. No. 16/943,821, filed Jul. 30, 2020, Pending. |
U.S. Appl. No. 16/943,871, filed Jul. 30, 2020, Pending, US 2020-0352920 A1. |
U.S. Appl. No. 16/725,282, filed Dec. 23, 2019, Pending, US 2020-0253973 A1. |
U.S. Appl. No. 16/870,384, filed May 8, 2020, Pending, US 2020-0354352 A1. |
U.S. Appl. No. 16/870,418, filed May 8, 2020, Pending, US 2020-0354346 A1. |
U.S. Appl. No. 16/902,989, filed Jun. 16, 2020, Pending. |
U.S. Appl. No. 16/991,644, filed Aug. 12, 2020, Pending. |
U.S. Appl. No. 17/028,641, filed Sep. 22, 2020, Pending, U.S. Pat. No. 10,966,966. |
U.S. Appl. No. 17/180,234, filed Feb. 19, 2021, Patented, U.S. Pat. No. 11,185,535. |
U.S. Appl. No. 17/180,241, filed Feb. 19, 2021, Pending. |
U.S. Appl. No. 17/504,133, filed Oct. 18, 2021, Pending. |
U.S. Appl. No. 17/583,977, filed Jan. 25, 2022, Pending. |
U.S. Appl. No. 17/583,985, filed Jan. 25, 2022, Pending. |
U.S. Appl. No. 17/727,307, filed Apr. 22, 2022, Pending. |
“A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies,” ClinicalTrials.gov, Jan. 12, 2018, pp. 1-11. Retrieved from the Internet: URL: <https://clinicaltrials.gov/ct2/show/NC>. |
“Additions and Corrections”, Journal of Medicinal Chemistry, 32(12):2583 (1989). |
“NHLBI LBC Computational Biophysics Scetion”, CHARMM Documentation Index, http://www.lobos.nih.gov/Charmm/chmdoc.html, printed Mar. 4, 2005. |
“Trilateral Project WM4—Comparative Studies in New Technologies: Report on Comparative Study on Protein 3-Dimensional Structure Related Claims—Annex 3: Comments of the USPTO”, Vienna, Austria, Nov. 4-8, pp. 58-79 (2002). |
Aklilu, et al., “Increased PTHRP Production by a Tyrosine Kinase Oncogene, Tpr-Met: Rose of the Ras Signaling Pathway”, The American Physiological Society, pp. E277-E283 (1996). |
Albericio, et al., “Synthesis of a Sulfaydantion Library”, J. Comb. Chem., 3:290-300 (2001). |
Almerico, et al., “On the Preparation of 1-aryl-2-heteroaryl- and 2-aryl-1-heteroaryl-pyrroles as Useful Building Blocks for Biologically Interesting Heterocycles”, Arkivoc, Rudy Abramovitch Issue, pp. 129-142 (2001). |
Antonescu, et al., “Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation,” Clinical cancer research : an official journal of the American Association for Cancer Research, 11(11):4182-4190 (2005). |
Anzai, et al., “Alkyl- and Arylthiation of Uracil and Indole”, J. Heterocyclic Chem., 16:567-569 (1979). |
Askew, et al., “Molecular Recognition with Convergent Functional Groups: 6. Synthetic and Structural Studies with a Model Receptor for Nucleic Acid Components”, J. Am. Chem., 111:1082-1090 (1989). |
Avruch, J. et al., “Ras Activation of the Raf Kinase: Tyrosine Kinase Recmitment of the MAP Kinase Cascade,” Recent Prag Harm. Res. (2001) 56: 127-155. |
Bai et al., “Targeting the KITactivating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation,” Leukemia (2013), vol. 27, pp. 278-285. |
Bais, et al., “Inhibition of Endogenous Wxalate Production: Biochemical Consideration of the Roles of Glycollate Oxidase and Lactate Dehydrogenase”, Clinical Science, 76:303-309 (1989). |
Baker, et al., “Irreversible Enzyme Inhibitors. 188. Inhibition of Mammalian Thymidine Phosphorylase”, Journal of Medicinal Chemistry, 14:612-616 (1971). |
Banks et al., Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFR inhibitor fortreatment of gastrointestinal stromal tumors, Sci. Transl. Med. 12, (2020). |
Barker, et al., “Characterization of pp60c-src Tyrosine Kinase Activities Using a Continuous Assay: Autoactivation of the Enzyme is an Intermolecular Autophosphorylation Process”, Biochemist , 35:14843-14851 (1995). |
Barvian, et al, “Pyrido[2,3-d]pyrimidin-7-one Inhibitors of Cyclin-Dependent Kinases,” J Med Chem. (2000) 43: 4606-4616. |
Bausch, et al., “Proton-Transfer Chemistry of Urazoles and Related Imides, and Diacyl H drazides”, J. Org. Chem., 56:5643-5651 (1991). |
Beghini, et al., “C-kit mutations in core binding factor leukemias,” Blood Journal, 95(2):726-727 (2000). |
Benvenuti, et al., “Crystallization of Soluble Proteins in Vapor Diffusion for X-Ray Crystallography”, Nature Protocols, 2(7):1633-1651 (2007). |
Blay, et al., “Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial”, Lancet Oncology, 21:923-934 (2020). |
Bolton, et al, “Chapter 17. Ras Oncogene Directed Approaches in Cancer Chemotherapy,” Ann. Rep. Med. Chem. (1994) 29: 165-174. |
Bosca, et al., “Circular Dichroism Analysis of Ligand-Induced Conformational Changes in Protein Kinase C”, Biochem. J., 290:827-832 (1993). |
Boschelli, et al., “4-Anilino-3-quinolinecarbonitriles: An Emerging Class of Kinase Inhibitors”, Current Topics in Medicinal Chemist , 2:1051-1063 (2002). |
Bourdon NEC, et al., “Synthesis and Pharmacological Evaluation of New Pyrazolidine-3,5-diones as AT 1 Angiotensin II Receptor Antagonists”, J. Med. Chem., 43:2685-2697 (2000). |
Boyer, “Small Molecule Inhibitors of KDR (VEGFR-2) Kinase: An Overview of Structure Activit Relationships”, Current Topics in Medicinal Chemist , 2:973-1000 (2002). |
Brady, et al., “Fast Prediction and Visualization of Protein Binding Pockets with PASS”. Journal of Computer-Aided Molecular Desi n, 14:383-401 (2000). |
Branford, et al., “High Frequency of Point Mutations Clustered Within the Adenosine Triphosphate-binding Region of BCR/ABL in Patients With Chronic Myeloid Leukemia or Ph-positive Acute Lymphoblastic Leukemia Who Develop Imatinib (ST1571)resistance,” Blood (2002) vol. 99, pp. 3472-3475. |
Brasher, et al., “C-Abul has High Intrinsic Tyrosine Kinase Activity that is Stimulated by Mutation of the Src Homology 3 Domain and by Autophosphorylation at Two Distinct Re ulator T rosines”, Journal of Biolo ical Chemistr , 275:35631-35637 (2000). |
Bullock, et al., “Prospects for Kinase Activity Modulators in the Treatment of Diabetes and Diabetic Complications”, Current Topics in Medicinal Chemistr , 2:915-938 (2002). |
Byron, et al., “The Synthesis of some Substituted Biphenyl-4-carboxylic Acids, 4-Biphenylylacetic Acids, and 4-Aminobiphenyls”, J. Chem. Soc. (C), Organic, pp. 840-845 (1966). |
Cardillo, et al., “Su lie 1,2-difenil-3.5-dichetopirazolidine”, Gazz. Chim., Ital., 9:973-985 (1966). |
Carr, J. B., et al., “Isoxazolc Anthelmintics,” .J /'vied. Chem (1977) vol. 20, No. 7, pp. 934-939. |
Chan et al., “Copper promoted C—N and C—O bond cross-coupling with phenyl and pyridylboronates,” Tetrahedron Letters (2003) vol. 44, pp. 3863-3865. |
Chan, “Promotion of Reaction of N—H Bonds with Triarylbismuth and Cupric Acetate,” Tetrahedron Letters (1996) vol. 37, No. 50, pp. 9013-9016. |
Chan, et al, “New N- and O-Arylations with Phenylboronic Acids and Cupric Acetate,” Tetrahedron Lett. (1998) 39: 2933-2936. |
Chen, et al., “Biochemical Evidence for the Autophosphorylation and Transphosphorylation of Transforming Growth Factor 13 Receptor Kinases”, Proc. Natl. Acad. Sci. USA, 92:1565-1569 (1995). |
Cheng, et al., “Novel Solution Phase Strategy for the Synthesis of Chemical Libraries Containinq Small Orqanic Molecules”, J. Am. Chem. Soc., 118:2567-2573 (1996). |
Cheng, et al., “Synthesis and SAR of Heteroaryl-phenyl-substituted Pyrazole Derivatives as Highly Selective and Potent Canine COX-2 Inhibitors”, Bioorganic & Medicinal Chemistry Letters, 16:2076-2080 (2006). |
Chu, et al., “Using Affinity Capillary Electrophoresis to Determine Binding Stoichiometries of Protein-Ligand Interactions”, Biochemistry, 33:10616-10621 (1994). |
Cirillo, et al. “The Non-Diaryl Heterocycle Classes of p38 MAP Kinase Inhibitors”, Current Topics in Medicinal Chemistry, 2:1021-1035 (2002). |
Clinical trial NCT03353753 Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)—clinicaltrials.gov—Nov. 27, 2017. |
Clinical trial NCT02571036—A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies—clinicaltrials.gov—Dec. 16, 2015. |
Clinical trial NCT02571036—A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies—clinicaltrials.gov—Feb. 10, 2016. |
Clinical trial NCT02571036—A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies—clinicaltrials.gov—May 25, 2017. |
Clinical trial NCT02571036—A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies—clinicaltrials.gov—Nov. 3, 2015. |
Clinical trial NCT02571036—A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies—clinicaltrials.gov—Oct. 29, 2015. |
Clinical trial NCT02571036—A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies—clinicaltrials.gov—Oct. 8, 2015. |
Clinical trial NCT02571036—A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies—clinicaltrials.gov—Sep. 17, 2018. |
Clinical trial NCT03353753 Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)—clinicaltrials.gov—Nov. 21, 2018. |
Closier, et al., “Nitrofuryl Heterocyclics. 1”, Journal of Medicinal Chemistry, 13(4):638-640 (1970). |
Cockerill, et al., “Small Molecule Inhibitors of the Class 1 Receptor Tyrosine Kinase Family”, Current Topics in Medicinal Chemistry, 2:1001-1010 (2002). |
Colton, et al., “Affinity Capillary Electrophoresis: A Physical-Organic Tool for Studying Interactions in Biomolecular Recognition”, Electrophoresis, 19:367-382 (1998). |
Corless, et al., “Biology of Gastrointestinal Stromal Tumors,” Journal of Clinical Oncology, 22(18):3813-3825 (2004). |
Cortes, et al., “Results of Imatinib Mesylate Therapy in Patients with Refractory or Recurrent Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrime, and Mveloproliferative Disorders”, Cancer, 97(11 ):2760-2766 (2003). |
Cortes, Javier, et al., “Eribulin Monotherapy Versus Treatment of Physician's Choice in Patients With Metastatic Breast Cancer (EMBRACE): A Phase 3 Open-label Randomised Study”, The Lancet, vol. 377, No. 9769, Mar. 1, 2011 (Mar. 1, 2011), pp. 914-923, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(11 )60070-6. |
Cross, et al., “Inhibition of Glycogen Synthase Kinase-3 by Insulin Mediated by Protein Kinase B”, Nature, 378:785-789 (1995). |
Cudney, “Preface: Protein Crystallization and Dumb Luck”, The Rigaku Journal, 16(1):1-7 (1999). |
Dajani, et al. “Crystal Structur of Glycogen Synthase Kinas 3j3: Structural Basis for Phosphate-Primed Substrate Specificity and Autoinhibition”, Cell, 105:721-732 (2001). |
Dajani, et al., “Structural Basis for Recruitment of Glycogen Synthase Kinase 313 to the Axin-APC Scaffold Complex”, EMBO, 22(3):494-501 (2003). |
Daley, et al., “Induction of Chronic Myelogenous Leukemia in Mice by the P21 otcriat, Gene of the Philadelphia Chromosome,” Science (Feb. 16, 1990) vol. 247, pp. 824-830. |
Database Registry [Online] Chemical Abstracts Service, Columbus, Ohio, US; May 27, 2010, XP002777425, retrieved from STN accession No. 1225278-16-9 RN (2 pages). |
Davies, H. et al, “Mutations of the BRAF gene in human cancer,” Nature (Jun. 2002) 41 7: 949-954. |
Davis, et al., “Iterative Size-Exclusion Chromatography Coupled with Liquid Chromatographic Mass Spectrometry to Enrich and Identify Tight-Binding Ligands from Complex Mixtures”, Tetrahedron, 55:11653-11667 (1999). |
de Boer, et al., “Synthesis and Characterization of Conjugated Mono- and Dithiol Oligomers and Characterization of Their Self-Assembled Monolayers”, Langmuir, 19:4272-4284 (2003). |
De Palma et al., “Angiopoietin-2 TIEs Up Macrophages in Tumor Angiogenesis” Clin Cancer Res; 17(16) Aug. 15, 2011. |
de Silva, et al., “Gastrointestinal Stromal Tumors (GIST): C-kin Mutations, CD117 Expression, Differential Diagnosis and Targeted Cancer Therapy with Imatinib”, Pathology Oncology Research, 9(1):13-19 (2003). |
Debiec-Rychter, et al., “Mechanisms of Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumors and Activity of the PKC412 Inhibitor Against Imatinib-Resistant Mutants,” Gastroenterology, 128(2):270-279 (2005). |
Deciphera Pharmaceuticals LLC, “DCC-2618, a small molecule inhibitor of normal and mutant KIT kinase for treatment of refractory gastrointestinal stromal tumors (GIST)” (Presented on Sep. 24, 2011 at GIST Summit 2011 on “Gastrointestinal stromal tumors.”). |
Deciphera Pharmaceuticals LLC, “Deciphera Pharmaceuticals announces positive top-line results from INVICTUS pivotal phase 3 clinical study of Ripretinib in patients with advanced gastrointestinal stromal tumors”, 1-3 (2019). |
Deciphera Pharmaceuticals LLC, “Deciphera Pharmaceuticals Initiates Pivotal Phase 3 Clinical Study of Ripretinib (DCC-2618) in Second-line Patients with Gastrointestinal Stromal Tumors (“INTRIGUE” Study)”, 1-2 (2018). |
Deciphera Pharmaceuticals LLC, “Qinlock Full Prescribing Information”, 1-18 (2020). |
Deng, et al., “Expression, Characterization, and Crystallization of the Pyrophosphate-Dependent Phosphofructo-1-Kinase of Borrelia Burgdorferi”, Archives of Biochemistry and Biophvsics, 371(2):326-331 (1999). |
Dess, et al., “A Useful 12-1-5 Triacetoxyperiodiane (the Dess-Martin Periodiane) for Selective Oxidation of Primary or Secondary Alcohols and a Variety of Related 12-1-5 Species”, J. Am. Chem., Soc., 113:7277-7287 (1991). |
Dong, J., Overcoming Resistance TO BRAF and MEK inhibitors by Simultaneous Suppression of CDK4. InTech. Jan. 30, 2013. Melanoma—From Early Detection to Treatment, Chapter 1; abstract; p. 7, second paragraph; p. 9, figure 4; DOI: 10.5772/53620. |
Dumas, “Preface”, Current Topics in Medicinal Chemistry (2002). |
Dumas, “Protein Kinase Inhibitors: Emerging Pharmacophores”, Exp. Opin. Ther. Patent, 11 :405-429 (2001). |
Dumas, et al., “Discovery of a New Class of p38 Kinase Inhibitors”, Bioorganic & Medicinal Chemistry Letters, 10:204 7-2050 (2000). |
Dumas, et al., “Recent Developments in the Discovery of Protein Kinase Inhibitors From the Urea Ciass,” Current Opinion in Drug Discovery & Development (2004) vol. 7, No. 5, pp. 600-616. |
Ettmayer, et al., “Lessons Learned from Marketed and Investigational Prodrugs,” Journal of Medicinal Chemistry (May 6, 2004) vol. 47, No. 10, pp. 2393-2404. |
Ewing, “Critical Evaluation of Search Algorithms for Automated Molecular Docking and Database Screeninq”, Journal of Computational Chemistry, 18(9):1175-1189 (1997). |
Examination Report in Indian Patent App. No. 11241/DELNP/2014 dated Apr. 1, 2019. |
Faderl et al., “The Biology of Chronic Myeloid Leukemia,” The New England Journal of Medicine (Jul. 15, 1999) vol. 341. No. 3. pp. 164-172. |
Farooqui, et al., “Interactions Between Neural Membrane Glycerophospholipid and Sphingolipid Mediators: A Recipe for Neural Cell Survival or Suicide”, Journal of Neuroscience Research, 85:1834-1850 (2007). |
Fathalla, “Synthesis of New Pyrazolo[1,5-a]pyrimidine Derivative Using 5-Aminouracil and Ketene Dithiacetal”, Arch Pharm Res, 22(6):571-574 (1999). |
Fathalla, et al., “Synthesis of New Uracil-5-Sulfonamide Derivatives and Immuno-Stimulatory Effect of a Chemically Modified Hemolymph of Biomphalaria Alexandrina on Schistosoma Manosi Infected Mice”, Arch Pharm Res., 26(5):358-366 (2003). |
Fathalla, et al., “Synthesis of New Uracil-5-Sulphonamide-p-Phenyl Derivatives and Their Effect on Biomphalaria alexandrine Snail's Nucleoproteins”, Arch. Pharm. Res., 23(2):128-138 (2000). |
Flatt, et al., “Synthesis of Thiol Substituted Oligoanilines for Molecular Device Candidates”, Tetrahedron Letters, 44:6699-6702 (2003). |
Fletcher, et al., “Diagnosis of Gastrointestinal Stromal Tumors: A Consensus Approach”, 33(5):459-465 (2002). |
Fletcher, et al., “KIT Mutations in GIS, Current Opinion in Genetics & Development,” Science Direct, p. 3-7 (2007). |
Frame, et al., “A Common Phosphate Binding Site Explains the Unique Substrate Specificity of GSK3 and Its Inactivation by Phosphorylation”, Molecular Cell, 7:1321-1327 (2001). |
Furyua, et al., “Addition of 4-Ethoxyimidazoles to Dimethyl Acetylenedicarboxylate and Transformation of the Adducts to Pyrimidian-5-yl Acetates”, Chem. Pharm. Bull., 36(5):1669-1675 (1988). |
Gajiwala, et al., “KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients,” Proceedings of the National Academy of Sciences of the USA 106(5):1542-1547 (2009). |
Garcia-Tellado, et al., “Molecular Recognition in the Solid Waste State: Controlled Assembly of Hydrogen-Bonded Molecular Sheets”, J. Am. Chem. Soc., 113:9265-9269 (1991). |
George, et al., “Initial Results of Phase 1 Study of DCC-2618, a Broad-Spectrum Kit and PDGFRA Inhibitor, in Patients (PTS) with Gastrointestinal Stromal Tumor (GIST) by Number of Prior Regimes”, European Society for Medical Oncology, 1-13 (2018). |
Gishizky, et al., “Efficient transplantation of BCR-ABL-induced Chronic Myelogenous Leukemia-like Syndrome in Mice,” Proc. Natl. Acad. Sci. (Apr. 1993) vol. 90, pp. 3755-3759. |
Gorre et al, “Clinical Resistance to STI-571Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification,” Science (Aug. 3, 2001) vol. 293, pp. 876-880. |
Greene, et al., “Chapter 7: Protection for the Amino Group”, in Protective Groups in Organic Synthesis, Third Edition, pp. 494-653 (1999). |
Griffith, et al., “TPAP: Tetra-n-propylammonium Perruthenate, A Mild and Convenient Oxidant for Alcohols”, Aldrichimica Acta, 23(1):13-19 (1990). |
Guzel, “Investigation of the Relationship Between the Inhibitory Activity of Glycolic Acid Oxidase (GAO) and its Chemical Structure: Electron-Topological Approach”, Journal of Molecular Structure, 366:131-137 (1996). |
Haar, et al., “Structure of GSK313 Reveals a Primed Phosphorylation Mechanism”, Nature Structural Bioloav, 8(7):593-596 (2001). |
Hackler, et al., “The Syntheses of 5-Amino-3-t-butylisothiazole and 3-Amino-5-t-butylisothiazole,” J. Heterocyc/ic Chem. (Nov.-Dec. 1989) vol. 26, pp. 1575-1578. |
Haesslein, et al., “Recent Advances in Cyclin-Dependent Kinase Inhibition. Purine-Based Derivatives as Anti-Cancer Agents. Roles and Perspectives for the Future”, Current Topics in Medicinal Chemistry, 2:1037-1050 (2002). |
Hearing Notice in Indian Patent App. No. 11241/DELNP/2014 mailed Jan. 24, 2020. |
Heegaard, et al., “Affinity Capillary Electrophoresis: Important Application Areas and Some Recent Developments”, Journal ofChromatoqraphy B, 715:29-54 (1998). |
Heinrich, et al., “Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors,” Journal of Clinical Oncology, 24(29):4764-4774 (2006). |
Heinrich, et al., “Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor,” Journal of Clinical Oncology, 26(33):5352-5359 (2008). |
Honda, et al., “Determination of the Association Constant of Monovalent Mode Protein-Sugar Interaction by Capillary Zone Electrophoresis”, Journal of Chromatography, 597:377-382 (1992). |
Hu, et al., “Capillary Electrophoresis for the Analysis of Biopolymers”, Anal., Chem., 74:2833-2850 (2002). |
Huang, et al., “Inhibition of Nucleoside Transport by Protein Kinase Inhibitors”, The Journal of Pharmacolo and Experimental Therapeutics, 304 2 :753-760 (2003). |
Hubbard, “Crystal Structure of the Activated Insulin Receptor Tyrosine Kinase in Complex with Peptide Substrate and ATP Analo”, EMBO, 16(18):5573-5581 (1997). |
Hubbard, et al., “Crystal Structure of the Tyrosine Kinase Domain of the Human Insulin Receptor”, Nature, 374:746-754 (1994). |
Hughes, et al., “Modulation of the Glycogen Synthase Kinase-3 Family by Tyrosine Phosphor lation”, EMBO, 12 2 :803-808 (1993). |
Huse et al, “The Conformational Plasticity of Protein Kinases,” Cell (May 3, 2002) vol. 109, pp. 275-282. |
Huse, et al., “Crystal Structure of the Cytoplasmic Domain of the Type I TGFI3 Receptor in Complex with FKBP12”, Cell, 96:425-436 (1999). |
Huse, et al., “The TGFI3 Receptor Activation Process: An Inhibitor- to Substrate-Binding Switch”, Molecular Cell, 8:671-682 (2001). |
Igarashi, et al., “Antimicrobial Activities of 2-arylthio-N-alkylmaleimides”, Journal of Industrial Microbiolo, 9:91-96 (1992). |
International Human Genome Sequencing Consortium, “Initial Sequencing and Analysis of the Human Genome”, Nature, 409:860-921 (2001). |
International Search Report and Written Opinion from PCT/US2012/041378, dated Sep. 17, 2012. |
International Search Report and Written Opinion from PCT/US2017/035005, dated Feb. 22, 2018. |
International Search Report and Written Opinion from PCT/US2019/016148, dated Apr. 17, 2019. |
International Search Report and Written Opinion from PCT/US2019/016161, dated Apr. 23, 2019. |
International Search Report and Written Opinion from PCT/US2020/045876, dated Oct. 22, 2020. |
International Search Report and Written Opinion from PCT/US2020/067557, dated Apr. 23, 2021. |
International Search Report and Written Opinion from PCT/US2020/067560, dated Apr. 23, 2021. |
International Search Report and Written Opinion from WO2008/034008 A3, dated Apr. 11, 2008. |
International Search Report issued for PCT/US2008/060833, dated Sep. 30, 2008. |
International Search Report issued for PCT/US2008/060867, dated Sep. 29, 2008. |
International Search Report issued for PCT/US2008/060896, dated Sep. 29, 2008. |
Ishida, et al., “Molecular Arrangement and Electrical Conduction of Self-Assembled Monola ers Made from Terphen I Thiols”, Surface Sciences, 514:187-193 (2002). |
Islip, et al., “Nitrofuryl Heterocyclics 3”, Journal of Medicinal Chemistry, 16(11):1309-1310 (1973). |
Jackson, et al., “N-Terminal Mutations Activate the Leukemogenic Potential of the M risto lated form of c-abl”, EMBO, 8(2):449-456 (1989). |
Jackson, et al., “Pyridinylimidazole Based p38 MAP Kinase Inhibitors”, Current Topics in Medicinal Chemist, 2:1011-1020 (2002). |
Janku Filip et al., “Pharmacokinetic-driven phase I study of DCC-2618 a pan-KIT and PDGFR inhibitor in patients (pts) with gastrointestinal stromal tumor (GIST) and other solid tumors,” J. Clin. Oncol. (2017) No. 15, Suppl 2515. |
Janku, et al., “Abstract CT058: Ripretinib (DCC-2618) pharmacokinetics (PK) in a Phase I study in patients with gastroinestinal stromal tumors (GIST) and other advanced malignancies: A retrospective evaluation of the PK effects of proton pump inhibitors (PPIs)”, American Association for Cancer Research, 79(13):1-4 (2019). |
Jiang, et al., ““Soft Docking”: Matching of Molecular Surface Cubes”, J. Mol. Biol., 219:79-102 (1991). |
Jiang, et al., “Synthesis and SAR Investigations for Novel Melanin-Concentrating Hormone 1 Receptor (MCH1) Antagonists Part 1. The Discovery of Arylacetamides as Viable Replacements for the Dihydropyrimidione Moiety of an HTS Hit”, J. Med. Chem., 50:3870-3882 (2007). |
Johnson, “Circular Dichroism Spectroscopy and the Vacuum Ultraviolet Region”, Ann. Rev. Phys. Chem., 29:93-114 (1978). |
Johnson, “Protein Secondary Structure and Circular Dichroism: A Practical Guide”, Proteins: Structure, Function, and Genetics, 7:205-214 (1990). |
Johnson, et al., “An Evaluation of the Effect of Light Stabilisers on the Exterior Durability of Polyester Powder Coatings for the Architectural Market”, Surface Coatings International, 3:134-141 (1999). |
Johnson, et al., “The Stereochemistry of Oxidation at Sulfur Oxidation of 2-Thiabicyclo[2.2.1]Hpetane”, Tetrahedron, 25:5649-5653 (1969). |
Katritzky, et al., “Novel Chromophoric Heterocycles Based on Maleimide and Naphthoquinone”, J. Heterocyclic Chem., 26:885-892 (1989). |
Kern, et al., “Synthese von Makromolekeln einheitlicher Brol3e. II Mitt: Syntheses neuer Diololigo-urethane nach dem Duplikationsverfahren”, Makromolekulara Chemie, 16:89-107 (1955). |
Kettle et al., “Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]aminolphenyl)-2-[4-(propan-2-yl)-1H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors” Journal of Medicinal Chemistry (2018), 61(19), 8797-8810. |
Kim, et al., “Solid Phase Synthesis of Benzamidine and Butylamine-Derived Hydantoin Libraries”, Molecular Diversitv, 3:129-132 (1998). |
Klayman, et al., “The Reaction of S-Methiodide Derivatives of Activated Thioureas with Hydroxylic Compounds. A Novel Synthesis of Mercaptans”, J. Org. Chem., 37(10):1532-1537 (1972). |
Kleywegt, et al., “Detection, Delineation, Measurement and Display of Cavities in Macromolecular Structures”, Acta Cryst, D50:178-185 (1994). |
Koch, et al., “QSAR and Molecular Modelling for a Series of Isomeric X-Sulfanilamido-1-phenylpyrazoles”, Quant. Struct. Act. Relat., 12:373-382 (1993). |
Kolch, W., “Meaningful relationships: the regulation of the Ras/Raf/MEKJERK pathway by protein interactions,” Biochern. J (2000) 351: 289-305. |
Konopka, et al., “Cell Lines and Clinical Isolates Derived From Ph-positive Chronic Myelogenous Leukemia Patients Express c-abl Proteins With a Common Structural Alteration,” Proc. Natl. Acad. Sci. (Mar. 1985) vol. 82, pp. 1810-1814. |
Krasovitskii, et al., “Synthesis and Spectral-Luminescence Properties of Hetarylethylene Derivatives of 2,5-Diphenyloxazole and 2,5-Diphenyl-1,3,4-Oxadiazole”, Khimiya Geterotsiklicheskikh Soedinenii, 5:617-621 (1982). |
Kuhn, et al., “The Genesis of High-Throughput Structure-Based Drug Discovery using Protein Crystallography”, Analytical Techniques, Current Opinion in Chemical Biology, 6:704-710 (2002). |
Kumar, et al., “P38 Map Kinases: Key Signalling Molecules as Therapeutic Targets for Inflammatory Diseases”, Nature Reviews Drug Discovery, 2:717-726 (2003). |
Kundrot, “Which Strategy for a Protein Crystallization Project”, CMLS, Cell. Mol. Life Sci., 61 :525-536 (2004). |
Kundu, et al., “Depropargylation Under Palladium-Copper Catatlysis: Synthesis of Diaryl Sulfides”, Tetrahedron, 57:5885-5895 (2001). |
Kurogi, et al., “Discovery of Novel Mesangial Cell Proliferation Inhibitors Using a Three-Dimensional Database Searchinq Method”, J. Med. Chem., 44:2304-2307 (2001). |
Kuse, et al., Synthesis of azide-fluoro-dehydrocoelentcrazine analog as a photoaffinitylabeling probe and photolysis of azide-fluoro-coelenterazine; Tetrahedron Lett. (2005) 61: 5754-5762. |
Kwong, et al., “A General, Efficient, and Inexpensive Catalyst System for the Coupling Aryl Iodides and Thiols”, Organic Letters, 4(20):3517-3520 (2002). |
Laskowski, “SURFNET: A Program for Visualizing Molecular Surfaces, Cavities, and Intermolecular Interactions”, Journal of Molecular Graphics, 13:323-330 (1995). |
Leca, et al., “A New Practical One-Pot Access to Sulfonimidates”, Organic Letters, 4(23):4093-4095 (2002). |
Lefevre, et al., “Roles of Stem Cell Factor/c-Kit and Effects of Glivec® /STI571 in Human Uveal Melanoma Cell Turmorigenesis”, Journal of Biological Chemistry, 279(30):31769-31779 (2004). |
Lesort, et al., “Insulin Transiently Increases Tau Phosphorylation: Involvement of Glycogen Synthase Kinase-3f3 and Fyn Tyrosine Kinase”, Journal of Neurochemistry, 72(2):576-584 (1999). |
Leung, et al., “The Difluoromethylensulfonic Acid Groups as a Monoanionic Phosphate Surrogate for Obtaining PTP1 B Inhibitors”, Bioorganic & Medicinal Chemistry, 10:2309-2323 (2002). |
Li, et al., “Targeting Serine/Threonine Protein Kinase B/Akt and Cell-cycle Checkpoint Kinases for Treating Cancer”, Current Topics in Medicinal Chemistry, 2:939-971 (2002). |
Li, et al., “The P190, {210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia-like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity”, J. Exp. Med., 189(9):1399-1412 (1999). |
Lim et al., “Current research and treatment for gastrointestinal stromal tumors” World Journal of Gastroenterology (2017), 23(27), 4856-4866 Publisher: Baishideng Publishing Group Inc. |
Link, et al., “Synthesis of 8-Substituted 5-Deazaflavins”, J. Heterocyclic Chem, 22:841-848 (1985). |
Lipinski, et al., “Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings”, Advanced Drug Delivery Reviews, 23:3-25 (1997). |
Longley et al., “Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm,” Nature Genetics, 12(3):312-314 (1996). |
Loren, et al., “NH-1,2,3-Triazoles from Azidomethyl Pivalate and Carbamates: Base-Labile N-Protecting Groups”, Synlett, 18:2847-2850 (2005). |
Lorenzi, et al., “Amino Acid Ester Prodrugs of 2-Bromo-5, 6-dichloro-1-([3-D-ribofuranosyl)benzimidazole Enhance Metabolic Stability In Vitro and In Vivo,” The Journal of Phannaco/ogy and Experimental Therapeutics (2005) vol. 314, No. 2 pp. 883-890. |
Lowinger, et al., “Design and Discovery of Small Molecules Targeting Raf-1 Kinase”, Current Pharmaceutical Design, 8:2269-2278 (2002). |
Ma, et al., “c-MET Mutational Analysis in Small Cell Lung Cancer: Novel Juxtamembrane Domain Mutations Regulating Cytoskeletal Functions”, Cancer Research, 63:6272-6281 (2003). |
Ma, et al., “c-Met: Structure, Functions and Potential for Therapeutic Inhibition”, Cancer and Metastasis Reviews, 22:309-325 (2003). |
Magnuson, et al, “The Raf-I serine/threonine protein kinase,” Seminars in Cancer Biology. (1994) 5: 247-253. |
Mallakpour, et al., “Uncatalyzed Polymerization of Bistriazolinediones with Electron-Rich Aromatic Compounds via Electrophilic Aromatic Substitution”, Journal of Polymer Science: Part A: Polymer Chemistry, 27:217-235 (1989). |
Mamaev, et al., “Synthesis of 2,5′-Bipyrimidines from Substituted 5-Cyanopyrimidines”, Khimiya Geterotsiklicheskikh Soedinenni, 24(3):371-375—(1988). |
March's Advanced Organic Chemisto.::: Reactions Mechanisms and Structure Fifth Edition, Smith and March Editors, Wiley-Interscience Publication (2001). |
March, et al., “Tautomerism”, from March's Advanced Organic Chemisto.::, 4th Edition, WileyInterscience, pp. 69-74. |
Martinez, et al., “First Non-ATP Competitive Glycogen Synthase Kinase 313 (GSK-313) Inhibitors: Thiadizolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimers Disease”, J. Med. Chem., 45(2002)1292-1299 (2002). |
Mattsson, et al., “Six X-Linked Agammaglobulinemia-Causing Missense Mutations in the Src Homology 2 Domain of Bruton's Tyrosine Kinase: Phosphotyrosine-Binding and Circular Dichroism Analysis”, Journal of Immunoloav, pp. 4170- 4177 (2000). |
Mazzieri, R et al., Targeting The ANG2/TIE2 Axis Inhibits Tumor Growth And Metastasis By impairing Angiogenesis And Disabling Rebounds Of Proangiogenic Myelid Cells. Cell. Apr. 12, 2001, vol. 19, pp. 512-526; DOI: 10.1016/j.ccr.2001.02.005 |
McPherson, “Current Approaches to Macromolecular Crystallization”, Eur. J. Biochem., 189:1-23 (1990). |
Medebielle, et al., “A Convenient Synthesis of Perfluoroalkylated and Fluorinated-Aryl Nitrogen Bases by Electrochemically Induced SRN1 Substitution”, J. Org. Chem., 61:1331-1340 (1996). |
Medebielle, et al., “A New Convenient Synthesis of 5-Aryl Uracils Using SRN1 Aromatic Nucleophilic Substitution”, Tetrahedron Letters, 34(21 ):3409-3412 (1993). |
Mikhaleva, et al., “Relative Reactivities of the Chlorine Atoms of 2,2′,4-Trichloro-4′,5-Dipyrimidinyl in its Reaction with Piperidine”, Khimiya Geterotsiklicheskikh Soedinenii, 6:821-826 (1979). |
Mol, “Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase,” The Journal of Biological Chemistry, 279(30):31655-31663 (2004). |
Morris, et al., “Automated Docking of Flexible Ligands to Macromolecules”, AutoDock Website, www.scripps.edu/mb/olson/doc/autodock/, printed Mar. 3, 2005. |
Morris, et al., “Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function”, Journal of Computational Chemistry, 19(14):1639-1662 (1998). |
Morstyn, et al., “Stem Cell Factor Is a Potent Synergistic Factor in Hematopoiesis”, Oncology, 51:205-214 (1994). |
Moss, et al., Basic Terminology of Stereochemistry, Pure & Appl. Chem., 6812):2193-2222 (1996). |
Muller, “Glossary of Terms Used in Physical Organic Chemistry”, Pure & Appl. Chem., 66(5):1077-1184 (1994). |
Muller, et al., “A General Synthesis of 4-Substituted 1,1-Dioxo-1,2,5-thiadiazolidin-3-ones Derived from α-Amino Acids”, J. Org. Chem., 54:4471-473 (1989). |
Murayama, et al., “JNK (c-Jun NH2 Terminal Kinase) and p38 During Ischemia Reperfusion Injury in the Small Intestine” Transplantation, 81(9):1325-1330 (2006). |
Mutlib, et al., “Disposition of 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2′-(methylsulfonyl)-[1, 1′-biphenyl]-4-yl]-3(trifluomethyl)-1 H-pyrazole-5-carboxamide (DPC 423) by Novel Metabolic Pathways. Characterization of Unusual Metabolites by Liquid Chromatography/Mass Spectrometrv and NMR”, Chem. Res. Toxicol., 15:48-62 (2002). |
Mutlib, et al., “P450-Mediated Metabolism of 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2′-(methylsulfonyl)-[1, 1′-biphenyl]-4-yl]-3(trifluomethyl)-1 H-pyrazole-5-carboxamide (DCP 423) and Its Analogues to Aldoximes. Characterization of Glutathione Conjugates of Postulated Intermediates Derived from Aloximes”, Chem. Res. Toxicol., 15:63-75 (2002). |
Nagano, M. et al. “Studies on Organic Sulfur Compounds. XIV. The Reaction of N-alkoxy-carbonyl-N′-(2-thiazolyl)thioureas with some oxidants.” Chemical and Pharmaceutical Bulletin. vol. 21, No. 11, pp. 2408-2416. ISSN: 0009-2363. Nov. 1973. |
Nagar, et al., “Crystal Structures of the Kinase Domain of c-Abl in Complex with the Small Molecule Inhibitors PD173955 and Imatinib (STI-571)”, Cancer Research, 62:4236-4243 (2002). |
Nagata, et al. “Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder,” Proc. Natl. Acad. Sci. USA, 92(23):10560-10564 (1995). |
Nager, et al., “Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase,” Cell (Mar. 21, 2003) vol. 112, pp. 859-871. |
Nakopoulou, et al., “c-Met Tyrosine Kinase Receptor Expression is Associated with Abnormal !3-catenin Expression and Favourable Prognostic Factors in Invasive Breast Carcinoma”, Histopatholoav, 36:313-325 (2000). |
Nantaka-Namirski, et al., “Condensation Reaction of Ethyl (4-Uracil)-Acetate with Ethyl Orthoformate”, ACTA Polon. Pharm XXVII, 28(5):455-463 (1971). |
National Academy of Sciences, “Abstracts of Papers Presented at the Autumn Meetinq, Nov. 14-16, 1960”, Science, 132:1488-1501 (1960). |
Nicolaou, et al., “Molecular Design and Chemical Synthesis of a Highly Potent Epothilone”, ChemMedChem, 1:41-44 (2006). |
Nikolaev, et al., “Solubility Polytherm in the System HNO3—H2O—(C4H9O)PO(C4H9)2”, Dokladv Akademii Nauk SSSR, 160(4):841-844 (1965). |
Ning, et al., “Activating Mutations of c-Kit at Codon 816 Confer Drug Resistance in Human Leukemia Cells,” Leukemia and Lymphoma, 41(5-6):513-522 (2001). |
Nofal, et al., “Synthesis of Novel Uracil-5-Sulphonamide Derivatives of Possible Biological Activity”, Egypt J. Chem., 33(4):375-380 (1990). |
Nowell et al., “A Minute Chromosome in Human Chronic Granulocytic Leukemia,” Science (Nov. 18, 1960) vol. 132, p. 1497. |
O'Dell, et al., “Treatment of Rheumatoid Arthritis with Methotrexate Alone, Sulfasalazine and Hydroxychloroquine, or a Combination of All Three Medications”, New England J. Med., 334(20):1287-1291(1996). |
O'Neill, “Targeting Signal Transduction as a Strategy to Treat Inflammatory Diseases”, Nature Review Drug Discovery, Published Online Jun. 9, 2006, www.nature.com/reviews/druqdisc. |
Office Action of U.S. Appl. No. 17/180,234 dated Apr. 29, 2021, 6 pages. |
Office Action of U.S. Appl. No. 17/180,241 dated Aug. 20, 2021, 11 pages. |
Office Action of U.S. Appl. No. 17/180,241 dated May 7, 2021, 9 pages. |
Okano, et al., “o-Bromophenylzinc Compound: A Readily Available and Efficient Synthetic Equivalent of o-Phenylene 1-Anion 2-Cation”, Tetrahedron Letters 39:3001-3004 (1998). |
Okishio, et al., “Differential Ligand Recognition by the Src and Phosphatidylinositol 3-Kinase Src Homology 3 Domains: Circular Dichroism and Ultraviolet Resonance Raman Studies”, Biochemistrv, 42:208-216 (2003). |
Okishio, et al., “Identification of Tyrosine Residues Involved in Ligand Recognition by the Phosphatidylinositol 3-Kinase Src Homology 3 Domain: Circular Dichroism and UV Resonance Raman Studies”, Biochemistrv, 40:15797-15804 (2001). |
Okishio, et al., “Role of the Conserved Acidic Residue Asp21 in the Structure of Phosphatidylinositol 3-Kinase Src Homolgy 3 Domain: Circular Dichroism and Nuclear Maqnetic Resonance Studies”, Biochemistrv 40:119-129 (2001). |
Okram, Barun et al: “A General Strategy for Creating “Inactive-Conformation” Ab1 Inhibitors” Chemistry&Biology (Cambridge, MA, US), 13(7), 779-786 CODEN: CBOLE2; ISSN: 1074-5521, 2006, XP002469183 table 1 the whole document. |
Palmer, Brian, D. et al: “Structure-Activity Relationships for 2-Anilino-6-Phenylpyrido[2,3-d]Pyrimidin-7(8H)-Ones As Inhibitors of the Cellular Checkpoint Kinase Wee1” Bioorganic & Medicinal Chemistry Letters, 15(7), 1931-1935 CODEN: BMCLE8; ISSN: 0960-894X, 2005, XP004789411 p. 1933. |
Parang, et al., “Mechanism-based Design of a Protein Kinase Inhibitor”, Nature Structural Bioloav, 8( 1 ):37-41 (2001). |
Pargellis, et al., “Inhibition of p38 MAP Kinase by Utilizing a Novel Allosteric Binding Site”, Nature Structural Bioloav, 9(4 ):268-272 (2002). |
Park, et al., “Mechanism of met Oncogene Activation”, Cell, 45:895-904 (1986). |
Pearlman, et al., “Assisted Model Building with Energy Refinement”, Amber Home Page, amber.scripts.edu. |
Pedersen, “The Preparation of Some N-Methyl-1,2,3-Triazoles”, Acta Chimica Scandinavica, 13(5):888-892 (1959). |
Peng, et al., “Identification of Novel Inhibitors of BCR-ABL Tyrosine Kinase via Virtual Screening”, Bioorganic & Medicinal Chemistry Letters, 13:3693-3699 (2003). |
Pereira, et al., “The Role of c-kit and Imatinib Mesylate in Uveal Melanoma”, Journal of Carcinogenesis, 4:19 (2005), downloaded from www.carcinogenesis.com/content/4/1/19, Sep. 3, 2008. |
Peyssonnaux, C. et al, “The RaflMEK/ERK pathway: new concepts of activation,” Biol. Cell (2001) 93: 53-62. |
Picard, et al., Inhibitors of Acyl-CoA: Cholesterol O-Acyltrasferase. 17. Structure-Activity Relationships of Several Series of Compounds. |
Pierrat, et al, “Solid Phase Synthesis of Pyridine-Based Derivatives from a 2-Chloro-5-Bromopyridine Scaffold,” .J Comb. Chem. (2005) 7 (6): 879-886. |
Pluk et al., “Autoinhibition of c-Abl,” Cell (Jan. 25, 2002) vol. 108, pp. 247-259. |
Ponzetto, et al., “A Novel Recognition Motif for Phosphatidylinositol 3-Kinase Binding Mediates Its Association with the Hepatocyte Growth Factor/Scatter Factor Receptor”, Molecular and Cellular Bioloav, 13(8):4600-4608 (1993). |
Raimbaul T, et al., “Effects of pH and KCI on the Conformations of Creatine Kinase from Rabbit Muscle”, Eur. J. Biochem., 234:570-578 (1995). |
Ranatunge, et al, “Synthesis and Selective Cyclooxygenase-2 Inhibitory Activity of a Series of Novel, Nitric Oxide Donor-Containing Pyrazoles,” J Med Chem. (2004) 47: 2180-2193. |
Reardon, D. et al., “Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent gliosblastoma”, J. Neurooncol. (2011), 101: pp. 57-66. |
Rebek, et al. “Convergent Functional Groups: Synthetic and Structural Studies”, J. Am. Chem. Soc., 107:7476-7481 (1985). |
Rebek, et al., “Convergent Functional Groups. 2. Structure and Selectivity in Olefin Epoxidation with Peracids”, J. Org. Chem., 51:1649-1653 (1986). |
Reed, et al., “Circular Dichroic Evidence for an Ordered Sequence Ligand/Binding Site Interactions in the Catalytic Reaction of the cAMP-Dependent Protein Kinase”, Biochemistry, 24:2967-2973 (1985). |
Regan, et al., “Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate”, J. Med. Chem., 45:2994-3008 (2002). |
Regan, et al., “Structure-Activity Relationships of the p38a MAP Kinase Inhibitor 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl )-3-[4-(2-morpholi n-4-yl-ethoxy)naph-thalen-1-yl]urea (BI RB 796)”, J. Med. Chem., 46:4676-4686 (2003). |
Reis, R. et al., “Molecular characterization of PDGFR-α/PDGF-A and c-KIT/SCF in gliosarcomas”, Cellular Oncology, 2005; 27: pp. 319-326. |
Remington, The Science and Practice of Pharmacy, Nineteenth Edition—1995, pp. 710-712. |
Rooney, et al., “Inhibitors of Gylcolic Acid Oxidase. 4-Substituted 3-Hydroxy-1 H-pyrrole-2,5-dione Derivatives”, J. Med. Chem., 26(5):700-714 (1983). |
Roux, et al. “ERK and p38 MAPK-Activated Protein Kinases: a Family of Protein Kinases with Diverse Biological Functions”, Microbiology and Molecular Biology Reviews, 68(2):320-344 (2004). |
Rowley, “A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Flourescence and Giemsa Staining,” Nature (Jun. 1, 1973) vol. 243, pp. 290-293. |
Rubin, et al., “Gastrointestinal stromal tumour,” The Lancet Oncology, 369(9574):1731-1741 (2007). |
Russell, et al., “3-[3-(Piperdin-1-yl)propyl]indoles as Highly Selective h5-HT1D Receptor”, J. Med. Chem., 42:4981-5001 (1999). |
Rutkowski, et al., “Gastrointestinal stromal tumours (GIST)—2018”, Oncology in Clinical Practice, 14(6):399-407 (2019). |
Saiga, et al.,“Consecutive Cross-Coupling of o-Phenylenedizinc Compound with Acyl and/or Aryl Halides in the Presence of Pd(0)-tris(2,4,6-trimethoxyphenyl)phosphine”, Tetrahedron Letters, 41 :4629-4632 (2000). |
Sakamoto, et al., “Condensed Heteroaromatic Ring Systems. XIX. Synthesis and Reactions of 5-(Tributylstannyl)Isoxazoles”, Tetrahedron, 4 7(28):5111-5118 (1991). |
Sakuma, et al., “c-kit Gene Mutations in Intracranial Germinomas”, Cancer Sci, 95(9):716-720 (2004). |
Salgia, “Studies on c-Kit and c-Met in Lung Cancer with Similarities to Stem Cells,” Microscopy Society of America, 11(2):1-30 (2005). |
Satsangi, et al., “1-(4-Substituted-thiazol-2-yl)hydatoins as Anti-inflammatory and CNC-Active Agents”, Pharmazie, 38:341-342 (1983). |
Sawyers, “Chronic Myeloid Leukemia,” The New England Journal of Medicine (Apr. 29, 1999) vol. 340, No. 17, pp. 1330-1340. |
Schindler et al., “Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase,” Science (Sep. 15, 2000) vol. 289, pp. 1938-1942. |
Schlosser, et al., “Regiochemically Flexible Substitutions of Di-, Tri-, and Tetrahalopy:ridines: The Trialkylsily Trick,” J Org. Chem. (2005) 70: 2494-2502. |
Schmidt, et al., “Germline and Somatic Mutations in the Tyrosine Kinase Domain of the MET proto-oncoqene in Papillary Renal Carcinomas”, Nature Genetics, 16:68-73 (1997). |
Schmidt, et al., “Novel Mutations of the MET Proto-oncogene in Papillary Renal Carcinomas”, Oncoqene, 18:2343-2350 (1999). |
Schneeweiss Mathias, et al., “The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis,” Haematologica (2018) vol. 103, No. 5, pp. 799-809. |
Schneeweiss Mathias, et al., “The Multi-Kinase Inhibitor DCC-2618 Inhibits Proliferation and Survival of Neoplastic Mast Cells and Other Cell Types Involved in Systemic Mastocytosis,” Blood (2016) vol. 128, No. 22, pp. 1965. |
Seimiya, et al., “Telomere Shortening and Growth Inhibition of Human Cancer Cells by Novel Synthetic Telomerase Inhibitors MST-312, MST-295, and MST-199”, Molecular Cancer Therapeutics, 1:657-665 (2002). |
Seminario, et al., “Theoretical Study of a Molecular Resonant Tunneling Diode”, J. Am. Chem. Soc., 122:3015-3020 (2000). |
Seto, et al. “2-Substituted-4-aryl-6, 7 ,8,9-tetrahydro-5/ 1-p)′Timido [ 4, 5-b] [ 1,5 Joxazocin-5-oneasastrncturallynewNK1 antagonist,” Biorg Nied Chem. Tea. (2005) 15: 1485-1488. |
Shah et al., “Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor,” Science (Jul. 16, 2004) vol. 305, pp. 399-401. |
Shah, et al., “Circular Dichroic Studies of Protein Kinase C and its Interactions with Calcium and Lipid Vesicles”, Biochimica et Biophvsica Acta, 1119:19-26 (1992). |
Shi et al. “Abnormal Diels-Alder Reaction of 5-Alkoxythiazoles with Highly Reactive Dienophiles; 4-Phenyl-3H-1,2,4-triazole-3,5(4H)-dione, Diethyl Azodicarboxylate, and Diethyl Oxomalonate”, Bull. Chem. Soc. Jpn., 65:3315-3321 (1992). |
Shinkai, et al., “Coenzyme Models, Part 45. Synthesis of Atropisomeric Flavins and their Novel Redox-induced Racemisation”, J. Chem. Soc. Perkin Trans., pp. 313-319 (1988). |
Shiozaki, et al., “Impaired Differentiation of Endocrine and Exocrine Cells of the Pancreas in Transgenic Mouse Expressing the Truncated Type II Activin Receptor”, Biochimica et Biophysica Acta, 1450:1-11 (1999). |
Sihto, et al., “KIT and Platelet-Derived Growth Factor Receptor Alpha Tyrosine Kinase Gene 1-30 Mutations and KIT Amplifications in Human Solid Tumors,” Journal of Clinical Oncology, 23(1):49-57 (2005). |
Sircar et al., “Synthesis of 4-Hydroxy-N-[5-(hydroxymethyl)-3-isoxazolyl]2-methyl-2H-1,2-bsnzo-thiazine-3-carboxamide 1,1-Dioxide and [(5-Methyl-3-isoxazolyl)amino]oxoacetic Acid. Major Metabolites of Isoxicam,” J. Org. Chem. (1985) vol. 50, pp. 5723-5727. |
Smith et al., “Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants,” Cancer Cell (2019), vol. 35, No. 5, pp. 738-759. |
STN Registry Database RN 1225278-16-9. |
Stout, et al., “High-Throughput Structural Biology in Drug Discovery: Protein Kinases”, Current Pharmaceutical Design, 10:1069-1082 (2004). |
Sugden, et al., ““Stress-Responsive” Mitogen-Activated Protein Kinases (c-Jun N-Terminal Kinases and p38 Mitogen-Activated Protein Kinases) in the Myocardium”, Circulation Research—Journal of the American Heart Association, 83:345-352 (1998). |
Tanis, et al., “Two Distinct Phosphorylation Pathways Have Additive Effects on Abl Family Kinase Activation”, Molecular and Cellular Bioloav, 23(11 ):3884-3896 (2003). |
Tanno, F. et al., “Evaluation of Hypromellose Acetate Succinate (HPMCAS) as a Carrier in Solid Dispersions”, Journal of Drug Development and Industrial Pharmacy, vol. 30, No. 1, pp. 9-17 (2004). |
Tarn, et al., “Analysis of KIT Mutations in Sporadic and Familial Gastrointestinal Stromal Tumors: Therapeutic Implications through Protein Modeling,” Clinical cancer research : an official journal of the American Association for Cancer Research, 11(10):3668-3677 (2005). |
Teague, “Implications of Protein Flexibility for Drug Discovery”, Nature Reviews, 2:527-541. |
Tian, et al., “Activating c-kit Gene Mutations in Human Germ Cell Tumors,” American Journal of Pathology, 154(6):1643-1647 (1999). |
Tominaga, et al., “General model for Estimation of the Inhibition of Protein Kinases Using Monte Carlo Simulations”, J. Med. Chem., 47:2534-2549 (2004). |
Tremblay, et al., “Efficient Solid-Phase Synthesis of Sulfahydantoins”, J. Comb. Chem., 4:429-435 (2002). |
Tsuzuki, et al., “Synthesis and Structure-Activity Relationships of Novel ?-Substituted 1,4-Dihydro-4-oxo-1-(2-thiazolyl)-1,8-napthyridine-3-carboxylic Acids as Antitumor Agents. Part 2”, J. Med. Chem., 47:2097-2109 (2004). |
Van Etten, “Cycling, Stressed-out and Nervous: Ceiiuiar Functions of c-Abi,” Trends in Cell Biology (May 1999) vol. 9, pp. 179-186. |
Venter, et al., “The Sequence of the Human Genome”, Science, 291:1304-1351, Feb. 16, 2001; Erratum, Jun. 8, 2001. |
Von Bubnoff, et al., “BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukemia to STI571. a prospective study,” The Lancet (Feb. 9, 2002) vol. 359, pp. 487-491. |
Waetzig, et al., “Review Article: Mitogen-Activated Protein Kinases in Chronic Intestinal Inflammation—Targeting Ancient Pathways to Treat Modern Diseases”, Aliment Pharmacol Ther, 18:17-32 (2003). |
Wan et al., “Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF,” Cell (Mar. 19, 2004) vol. 116. pp. 855-867. |
Wardelmann, “Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations,” The Lancet Oncology, 6(4):249-251 (2005). |
Welker, et al., “Glucocorticoid-Induced Modulation of Cytokine Secretion from Normal and Leukemic Human Myelomonocytic Cells”, Int. Arch. Allergy Immunol, 109:110-115 (1996). |
Wentland, et al., “3-Quinolinecarboxamides. A Series of Novel Orally-Active Antiherpetic Agents”, J. Med. Chem., 36:1580-1596 (1993). |
Wilson, et al., “The Structural Basis for the Specificity of Pyridinylimidazole Inhibitors of p38 MAP Kinase”, Chemistry & Biology, 4(6):423-431 (1997). |
Wilson, et el., “Laser-Jet Delayed Trapping: Electron-Transfer Trapping of the Photoenol from 2-Methylbenzophenone”, J. Am. Chem. Soc., 109:4743-4745 (1987). |
Wolter, et al., “Copper-Catalyzed Coupling of Aryl Iodides with Aliphatic Alcohols”, Organic Letters, 4(6):973-976 (2002). |
Wrana, et al., “Mechanism of Activation of the TGF-B Receptor”, Nature, 370:341-347 (1994). |
Wu, et al., “Discovery of a Novel Family of CDK Inhibitors with the Program LIDAEUS:Structual Basis for Ligand-Induced Disordering of the Acivation Loop”, Structure, 11:399-410 (2003). |
Yang, et al., “Molecular Mechanism for the Regulation of Protein Kinase B/Akt by Hvdrophobic Motif Phosphorylation”, Molecular Cell, 9:1227-1240 (2002). |
Yang, et al., “Palladium-Catalyzed Amination of Arly Halides and Sulfonates”, Journal of Organometallic Chemistry, 576:125-146 (1999). |
Yarden, et al., “Human Proto-oncogene c-kit: a New Cell Surface Receptor Tyrosine Kinase for an Unidentified Ligand”, The EMBO Journal, 6(11):3341-3351 (1987). |
Yoneda, et al., “A New Synthesis of Purines”, J.C.S. Chem. Comm., pq. 551 (1974). |
Yonezawa, et al., “Synthesis of Sequentially Controlled Isomeric, Wholly aromatic Polyketones Composed of 2-trifluoromethylbiphenylene and 2,2′-dimethoxybiphenylene Units”, Reactive & Functional Polymers, 52:19-30 (2002). |
Yoshimoto, et al., “Correlation Analysis of Baker's Studies on Enzyme Inhibition. 2. Chymotrypsin, Trypsin, Thymidine Phosphorylase, Uridine Phosphorylase, Thimidylate Synthetase, Cytosine Nucleoside Deaminase, Dihodrofolate Dehydrogenase, Glutamate Dehydrogenase, Lactate Dehydrogenase, and Glyceraldehydephosphate Reductase, Malate Dehydroqenase”, Journal of Medicinal Chemistrv, 19(1 ):71-98 (1976). |
Yoshino, et al., “Organic Phosphorous Compounds. 2. Synthesis and Coronary Vasodilator Activity of (Benzothiazolybenzyl) Phosphonate Derivatives”, J. Med. Chem., 32:1528-1532 (1989). |
Yu, et al., “Frequency of TPR-MET Rearrangement in Patients with Gastric Carcinoma and in First-Degree Relatives”, Cancer, 88(8):1801-1806 (2000). |
Zaidi, et al., “New Anti-Mycobacterial Hydantoins”, Pharmazie, 35:755-756 (1980). |
Zhen, et al., “Structural and Functional Domains Critical for Constitutive Activation of the HGF-Receptor (Met)”, Oncoqene, 9(6):1691-1697 (1994). |
Zinner, et al., “Zur Weiteren Kenntnis Bicyclischer 3.5-Dioxopyrazolidine”, Die Pharmazie, 25(5):309-312 (1970). |
Zustovich, F. et al., “Sorafenib plus Daily Low-dose Temozolomide for Relapsed Glioblastoma: A Phase II Study”, Anticancer Research (2013), 33: pp. 3487-3494. |
Zvilichovsky, et al., “Aminolysis and Polymerization of 3-(p-Toluenesulfonoxy) Hydantoin”, Israel Journal of Chemistry, 7:547-554 (1969). |
Number | Date | Country | |
---|---|---|---|
63023921 | May 2020 | US | |
63023936 | May 2020 | US | |
62968927 | Jan 2020 | US | |
62968945 | Jan 2020 | US | |
62936018 | Nov 2019 | US | |
62926281 | Oct 2019 | US | |
62904198 | Sep 2019 | US | |
62885797 | Aug 2019 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 17028640 | Sep 2020 | US |
Child | 17180218 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 17727307 | Apr 2022 | US |
Child | 17735862 | US | |
Parent | 17583985 | Jan 2022 | US |
Child | 17727307 | US | |
Parent | 17180218 | Feb 2021 | US |
Child | 17583985 | US | |
Parent | PCT/US2020/045876 | Aug 2020 | US |
Child | 17028640 | US |